,Canonical_Smiles,drug_name,drug_type,Label
0,N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,Chlorhexidine,Methyltransferase-Inhibitor,negative
1,COc1cc2c(cc1OC)C(=O)[C@H](CC1CCN(Cc3ccccc3)CC1)C2,Donepezil,2D6-Substrate,negative
2,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,Docetaxel,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
3,CO[C@H]1C=CO[C@]2(C)Oc3c(C)c(O)c4c(O)c(cc(O)c4c3C2=O)NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,Rifamycin,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
4,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,9_cis_retinoic_acid,2C9-Substrate,negative
5,Cc1cnc2ccc3c(nc(N)n3C)c2n1,2_amino_3_8_dimethylimidazo_4_5_f_quinoxaline,1A2-Substrate,negative
6,NN=c1[nH]ncc2ccccc12,Hydralazine,Methyltransferase-Inducer,negative
7,CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,Lisuride,2D6-Substrate,negative
8,CCCC(=O)O,Hydroxybutyric Acid,Monocarboxylate_transporter_1-Substrate,negative
9,COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12,Carvedilol,2E1-Substrate,negative
10,CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N,Retigabine,1A1-Substrate,negative
11,O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,Aripiprazole,P450_HFLA-Substrate,negative
12,CC1(C)[C@@H](C=C(Br)Br)[C@H]1C(=O)O[C@H](C#N)c1cccc(Oc2ccccc2)c1,Decamethrin,1A2-Substrate,negative
13,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3[C@@H](CC)C[C@@]21C,org_4060,3A4-Substrate,negative
14,CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12,Mepacrine,Methyltransferase-Inhibitor,negative
15,COc1ccc2c(C[n+]3ccccc3)cc(=O)oc2c1,MMPyrC,2D6-Substrate,negative
16,NC1=NC[C@@H]2c3ccccc3Cc3ccccc3N12,Epinastine,2D6-Inhibitor,negative
17,O=C(NC(Cc1cc(=O)[nH]c2ccccc12)C(=O)O)c1ccc(Cl)cc1,Rebamipide,-,negative
18,NCc1ccc(C(=O)O)cc1,Aminomethylbenzoic Acid,Solute_carrier_family_15_member_1-Inhibitor,negative
19,Cc1ccc(O)c([C@@H](CCN(C(C)C)C(C)C)c2ccccc2)c1,Tolterodine,2D6-Substrate,negative
20,C[C@@H](N)Cc1ccccc1,Amfetamine,2D6-Inhibitor,negative
21,COc1ccc(-c2oc3cc(O)cc(O)c3c(=O)c2O)cc1O,tamarixetin,2C9-Substrate,negative
22,Clc1ccc(Cl)c(-c2cc(Cl)c(Cl)cc2Cl)c1,PCB_101,3A4-Substrate,negative
23,CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21,Emedastine,-,negative
24,CCOP(=O)(OCC)Oc1ccc([N+](=O)[O-])cc1,Paraoxon,2E1-Substrate,negative
25,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)[C@@H]1c1cccc([N+](=O)[O-])c1,Manidipine,2D6-Inhibitor,negative
26,CSCCC(NC(=O)C(CC(C)C)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CC(=O)O)NC(=O)C(CCC(N)=O)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(N)=O)NC(=O)C(CO)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)O)C(C)O,Glucagon,GST-Inhibitor,negative
27,CC[C@H](C)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CO)NC(=O)[C@H]1CCCN1C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN)[C@H](C)CC)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O)c1ccc(OS(=O)(=O)O)cc1,Pancreozymin (cholecystokinin),Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
28,COc1ccc(OC(F)(F)F)cc1CN[C@H]1CCCN[C@H]1c1ccccc1,cp_122_721,2D6-Substrate,negative
29,CC(Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,Tenofovir,-,negative
30,O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1,Phenytoin,CP2CI-Substrate,negative
31,Cc1c[nH]c2ccccc12,3_methylindole,2E1-Substrate,negative
32,Cc1cccc(C)c1NC(=O)[C@H](C)N,Tocainide,-,negative
33,Cn1c(=O)[nH]c2ncn(C)c2c1=O,Paraxanthine,-,negative
34,CCC(=C(CC)c1ccc(O)cc1)c1ccc(O)cc1,Diethylstilbestrol,19A-Inducer,negative
35,CN1CCN(C(=O)NC(Cc2ccccc2)C(=O)NC(C=CS(=O)(=O)c2ccccc2)CCc2ccccc2)CC1,K11777,2E1-Substrate,negative
36,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,Paclitaxel,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
37,CCC(=O)O[C@H]1[C@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@@H]3[C@@H](OC)[C@H](OC(=O)CC)CC(=O)O[C@H](C)CC=CC=C[C@H](OC(C)=O)[C@H](C)C[C@@H]3CC=O)[C@H](O)[C@H]2N(C)C)C[C@@]1(C)OC(C)=O,Miocamycin,3A4-Inhibitor,negative
38,COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC,Vernakalant,2D6-Substrate,negative
39,Clc1ccc([C@H](Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1,Isoconazole,19A-Inhibitor,negative
40,CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)C=CC=CC[C@@H](C)OC(=O)C[C@H]1O,Spiramycin,3A4-Substrate,negative
41,Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1,Zalcitabine,P450_HFLA-Substrate,negative
42,CC1=C(C)C(=O)C([C@H](CCCCCC(=O)O)c2ccccc2)=C(C)C1=O,Seratrodast,2C19-Inhibitor,positive
43,N=C(N)NC(=N)NCCc1ccccc1,Phenformin,2D6-Substrate,negative
44,CCC(=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1,Methadone,CP2CI-Substrate,negative
45,O=c1[nH]c(=O)n(C2CCCO2)cc1F,tegafur,2E1-Substrate,negative
46,C#CCNC1CCc2ccccc21,Rasagiline,1A2-Substrate,negative
47,CC[C@@]1(c2ccccc2)C(=O)NC(=O)N(C)C1=O,Methylphenobarbital,2C19-Inhibitor,positive
48,O=C1OC(c2ccc(O)c(S(=O)(=O)O)c2)(c2ccc(O)c(S(=O)(=O)O)c2)c2c(Br)c(Br)c(Br)c(Br)c21,Sulfobromophthalein,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
49,CCCO,Propanol,-,negative
50,COc1cc([C@H]2c3cc4c(cc3C[C@@H]3COC(=O)[C@H]32)OCO4)cc(OC)c1OC,Podophyllotoxin,2C19-Substrate,negative
51,N#Cc1nn(-c2c(Cl)cc(C(F)(F)F)cc2Cl)c(N)c1[S@](=O)C(F)(F)F,fipronil,2C19-Substrate,negative
52,O=c1c(O)c(-c2ccccc2)oc2cc(O)cc(O)c12,galangin,2C9-Substrate,negative
53,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C=O)C(C)(C)CCC1,9_cis_retinal,2C19-Substrate,negative
54,Cc1ccc(S(=O)(=O)N(C)c2ccnn2-c2ccccc2)cc1,DMZ,2C19-Substrate,negative
55,NC[C@@H](O)c1ccc(O)c(O)c1,Norepinephrine,19A-Inhibitor,negative
56,C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1,cinnarizine,2D6-Substrate,negative
57,C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,Bicalutamide,2C19-Inhibitor,positive
58,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,Fluticasone,-,negative
59,c1ccc(C2(N3CCCCC3)CCCCC2)cc1,Phencyclidine,-,negative
60,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1,all_trans_retinoic_acid,2C9-Substrate,negative
61,Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,Cladribine,ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
62,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,Amoxicillin,Solute_carrier_family_22_member_6-Substrate,negative
63,COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12,Amsacrine,2D6-Substrate,negative
64,NC(=O)CC[C@H](N)C(=O)O,Levoglutamide,Neutral_amino_acid_transporter_B0-Substrate,negative
65,CC(C)n1c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,fluvastatin,2D6-Substrate,negative
66,O=c1[nH]c(=O)n([C@H]2CCCO2)cc1F,Tegafur,2E1-Substrate,negative
67,O=C1C(CCSc2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1,sulfinpyrazone_sulfide,2C9-Substrate,negative
68,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)[C@@H]1c1cccc([N+](=O)[O-])c1,Nicardipine,2C19-Inhibitor,positive
69,Cc1onc(-c2c(Cl)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12,Dicloxacillin,Multidrug_resistance_protein_1-Substrate,negative
70,CC(Cc1ccccc1)N(C)Cc1ccccc1,Benzfetamine,-,negative
71,Cc1ncc([N+](=O)[O-])n1C[C@H](O)CCl,Ornidazole,P450_HFLA-Substrate,negative
72,CC(=O)[C@@H]1CC[C@@H]2[C@H]3CCC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C,Progesterone,2C19-Inhibitor,positive
73,CSCC[C@H](N)C(=O)O,Methionine,GST-Inducer,negative
74,CN(CC=CC#CC(C)(C)C)Cc1cccc2ccccc12,Terbinafine,19A-Inhibitor,negative
75,C[C@H](C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1,Pirprofen,UGT-Substrate,negative
76,CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1,NE_100,2D6-Substrate,negative
77,Cc1nc2c([nH]1)c(=O)n(C)c(=O)n2CC1CCCCC1,BRN_4201400,1A2-Substrate,negative
78,CC(NC(N)=O)c1cc2ccccc2s1,ABT_66193,2D6-Substrate,negative
79,COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@H]2CCN(Cc3ccccc3)C2)[C@@H]1c1cccc([N+](=O)[O-])c1,Barnidipine,2C19-Inhibitor,positive
80,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl,Lindane,N_acetyltransferase-Inducer,negative
81,CC(C)N=C(N)N=C(N)Nc1ccc(Cl)c(Cl)c1,Chlorproguanil,-,negative
82,COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(C)CC3,dextromethorphan,2C9-Substrate,negative
83,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,Aceclofenac,-,negative
84,CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O,Tenoxicam,-,negative
85,Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1,Sulfadiazine,2E1-Substrate,negative
86,C=C(C)[C@@H]1CC=C(C)CC1,limonene_S,2C19-Substrate,negative
87,CNC[C@H](O)c1ccc(O)c(O)c1,Epinephrine,SUL-Substrate,negative
88,CC(=O)O,Acetic Acid,2E1-Substrate,negative
89,CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@H]1OC,miocamycin_Mb6,3A4-Substrate,negative
90,CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)[nH]c(N)nc21,Valaciclovir,Solute_carrier_family_15_member_2-Substrate,negative
91,Clc1ccc(C(c2ccc(Cl)cc2)C(Cl)(Cl)Cl)cc1,Clofenotane,19A-Inhibitor,negative
92,CN1CCCN=C1C=Cc1cccs1,Pyrantel,2D6-Substrate,negative
93,Cc1ccc2c(=O)c3cccc(CC(=O)O)c3oc2c1C,DMXAA,1A2-Substrate,negative
94,CCN(CCO)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12,Hydroxychloroquine,2D6-Inhibitor,negative
95,C[C@@H]1O[C@@]2(CS1)CN1CCC2CC1,SNI_2011_R_R,2D6-Substrate,negative
96,Cc1ncc([N+](=O)[O-])n1CCO,Metronidazole,-,negative
97,CC(C)(C)NCC(O)COc1ccccc1C1CCCC1,Penbutolol,2D6-Substrate,negative
98,CC(=O)C[C@H](c1ccccc1)c1c(O)c2ccccc2oc1=O,Warfarin,2C19-Inhibitor,positive
99,Cc1cc(CC(=O)O)n(C)c1C(=O)c1ccc(Cl)cc1,Zomepirac,3A4-Substrate,negative
100,CCc1cccc2cc([C@H](O)CNC(C)(C)C)oc12,bufuralol_R,2D6-Substrate,negative
101,O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1,Pitavastatin,UGT-Inhibitor,negative
102,Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1,Sulfamerazine,-,negative
103,CCN[C@@H]1C[C@@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,Dorzolamide,2E1-Substrate,negative
104,CN1CCC[C@H](n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,Azelastine,2C19-Inhibitor,positive
105,NC(=O)c1c(Cl)c(-c2cccnc2)n2c1C(O)CCC2,RPR_127025,3A4-Substrate,negative
106,O=S(Cc1ccccn1)c1nc2ccccc2[nH]1,Timoprazole,-,negative
107,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,Irbesartan,2D6-Inhibitor,negative
108,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O,Estriol,P450_HFLA-Substrate,negative
109,CCn1cc(C(=O)O)c(=O)c2cnc(N3CCNCC3)nc21,Pipemidic acid,-,negative
110,CC(C)NC[C@H](O)COc1cccc2ccccc12,propranolol_S,2D6-Substrate,negative
111,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6CC[C@]7(C)[C@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,Digitoxin,SUL-Substrate,negative
112,NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NC(Cc1ccccc1)NS2(=O)=O,Bendroflumethiazide,Methyltransferase-Inhibitor,negative
113,C[N+](C)([O-])CCCN1c2ccccc2CCc2ccccc21,Imipramine Oxide,1A2-Substrate,negative
114,CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)NC1=O)C(C)C,Insulin (human),Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inducer,negative
115,O=C(NC[C@@H]1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F,Flecainide,2D6-Substrate,negative
116,CCOc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314,Ethylmorphine,P450_HFLA-Substrate,negative
117,CN(C)CCCN1c2ccccc2Sc2ccccc21,promazine,2E1-Substrate,negative
118,O=[S@](Cc1cc(OCC2CC2)ccn1)c1nc2ccc(F)cc2[nH]1,H_259_31_R,2C19-Substrate,negative
119,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,losartan,2C9-Substrate,negative
120,S=c1[nH]cnc2nc[nH]c12,Mercaptopurine,Solute_carrier_family_28_member_3-Substrate,negative
121,CC(C)(N)Cc1ccccc1,Phentermine,2D6-Inhibitor,negative
122,OC(O)C(Cl)(Cl)Cl,Chloral hydrate,-,negative
123,COc1ccc(CC(C)N)cc1,4_methoxy_amphetamine,2D6-Substrate,negative
124,COP(=S)(OC)SCn1nnc2ccccc2c1=O,azinphosmethyl,2C19-Substrate,negative
125,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,Olanzapine,2C19-Inhibitor,positive
126,CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1,Albendazole,2D6-Substrate,negative
127,CN[C@@]1(c2ccccc2Cl)CCCCC1=O,Ketamine,2D6-Substrate,negative
128,Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C,Riboflavin (vit B2),ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
129,COC(F)(F)C(Cl)Cl,Methoxyflurane,2E1-Substrate,negative
130,C[C@H](C(=O)O)c1ccc(C(=O)c2cccs2)cc1,Suprofen,-,negative
131,CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,Dronabinol,-,negative
132,CNC(=O)Oc1cccc2ccccc12,carbaryl,2E1-Substrate,negative
133,c1cnc2cc3c(cc2n1)[C@H]1CNC[C@@H]3C1,Varenicline,Methyltransferase-Inhibitor,negative
134,COc1ccc([C@H](CC(=O)O)N2CCN(CCCc3ccc4c(n3)NCCC4)C2=O)cn1,compound_A,2D6-Substrate,negative
135,COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,omeprazole_S,2C19-Substrate,negative
136,Cc1ccc(C(C)C)cc2c(C)ccc1-2,Guajazulen,1A2-Substrate,negative
137,CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1,Cyproheptadin,UGT-Substrate,negative
138,O=C(CO)NCCCOc1cccc(CN2CCCCC2)c1,Roxatidine,2D6-Substrate,negative
139,C=CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_13,3A4-Substrate,negative
140,Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,Pemetrexed,Proton_coupled_folate_transporter-Substrate,negative
141,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C,Ursodeoxycholic Acid,2E1-Inducer,negative
142,COc1ccc2ccc(=O)oc2c1,7_methoxy_coumarin,2E1-Substrate,negative
143,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,Azacitidine,Methyltransferase-Inhibitor,negative
144,C[C@@H](O[C@@H]1OCCN(Cc2nc(=O)[nH][nH]2)[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,Aprepitant,2C19-Inhibitor,positive
145,CCCc1ccc2ccccc2n1,2n_propylquinoline,2E1-Substrate,negative
146,Nc1nc2ccc(OC(F)(F)F)cc2s1,Riluzole,-,negative
147,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC,Remoxipride,2D6-Substrate,negative
148,O=C(O)c1ccccc1O,Salicylic Acid,2E1-Inducer,negative
149,CNCCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,desmethyl_citalopram,2D6-Substrate,negative
150,Oc1nc2cc(Cl)ccc2o1,Chlorzoxazone,2E1-Inhibitor,negative
151,Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1,Ambroxol,-,negative
152,O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1,Indoramin,2D6-Substrate,negative
153,NC(=O)c1cccnc1,Nicotinamide,2E1-Inhibitor,negative
154,CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,Brinzolamide,-,negative
155,O=c1cc(C(F)(F)F)c2ccc(OCc3ccccc3)cc2o1,7_benzyloxy_4_trifluoromethyl_coumarin,2C19-Substrate,negative
156,CNS(=O)(=O)Cc1ccc2[nH]cc(CCCN3CCN(c4ncncc4OC)CC3)c2c1,Avitriptan,2D6-Substrate,negative
157,CC1(C)[C@H](C=C(Cl)Cl)[C@H]1C(=O)O[C@H](C#N)c1cccc(Oc2ccccc2)c1,Cypermethrin,1A2-Substrate,negative
158,COSc1cn(C)c2cc(F)ccc2c1=O,Flosequinan,-,negative
159,CN(C)CCOC(c1ccccc1)c1ccccc1,Diphenhydramin,2D6-Substrate,negative
160,CCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,Hydrocortisone Aceponate,3A4-Substrate,negative
161,CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1,Bisoprolol,2D6-Substrate,negative
162,CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)C3=CCC=CC3)[C@H]2SC1,Cefradine,Solute_carrier_family_15_member_1-Inhibitor,negative
163,CC(CF)NCC(O)COc1cccc2ccccc12,fluoro_propranolol,2D6-Substrate,negative
164,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,Morphine,2D6-Substrate,negative
165,COc1ccc2c(c1)c(CC(=O)NCC(O)c1ccccc1)c(C)n2C(=O)c1ccc(Cl)cc1,2_hydroxy_indomethacin_phenethylamide,2D6-Substrate,negative
166,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,Benzbromarone,-,negative
167,O=C(O)CCCC[C@@H]1CCSS1,Tioctic Acid,GST-Inducer,negative
168,CC(NCC(O)COc1cccc2ccccc12)C(F)F,difluoro_propranolol,2D6-Substrate,negative
169,CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13,Nicergoline,2D6-Substrate,negative
170,CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,Irinotecan,P450_HFLA-Substrate,negative
171,Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1,Thiamine (vit B1),P450_HP-Inducer,negative
172,OCc1cc([C@@H](O)CNCCCCCCOCCCCc2ccccc2)ccc1O,Salmeterol,P450_HFLA-Substrate,negative
173,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21,Pefloxacin,-,negative
174,Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,Adenosine,Sodiumbile_acid_cotransporter-Inducer,negative
175,COc1cc(N[C@H](C)CCCN)c2ncccc2c1,Primaquine,GST-Inhibitor,negative
176,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,pregnenolone,2D6-Substrate,negative
177,C[C@@H]1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1,Argatroban,Methyltransferase-Inducer,negative
178,CN(C)CC(Oc1ccccc1)Oc1ccccc1,Medifoxamine,-,negative
179,COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C,vicriviroc,2C9-Substrate,negative
180,CC[C@H](c1ccccc1)c1c(O)c2ccccc2oc1=O,Phenprocoumon,-,negative
181,CC(=O)OCC[N+](C)(C)C,Acetylcholin,Methyltransferase-Inducer,negative
182,CC(C)(C)NC[C@H](O)COc1cccc2c1CCC(=O)N2,Carteolol,2D6-Inhibitor,negative
183,COCc1c(C(=O)OC(C)C)ncc2[nH]c3ccc(OCc4ccccc4)cc3c12,Abecarnil,-,negative
184,CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(=O)O,Bezafibrate,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
185,COc1cc([C@H]2Oc3cc([C@H]4Oc5cc(O)cc(O)c5C(=O)[C@@H]4O)ccc3O[C@@H]2CO)ccc1O,Silymarin,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
186,CCN(CC)CCc1nc(-c2ccccc2)no1,Oxolamine,1B1-Inducer,negative
187,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@H](O)[C@@]1(C)O,erythromycin,3A4-Substrate,negative
188,COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC,Trimetrexate,-,negative
189,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CCO,Retinol (vit A),2C19-Inhibitor,positive
190,C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(C(F)(F)F)ccc1C(F)(F)F,Dutasteride,-,negative
191,CS(C)=O,Dimethyl Sulfoxide,2C19-Inhibitor,positive
192,CCC1(c2ccccc2)C(=O)NC(=O)NC1=O,Phenobarbital,4A11-Inducer,negative
193,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1,all_trans_retinal,2D6-Substrate,negative
194,CC[C@H](C)[C@H]1NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@@H](CCC(N)=O)NC1=O,Oxytocin,Solute_carrier_family_12_member_2-Inducer,negative
195,Fc1ccc(C(c2ccc(F)cc2)N2CCN(CC=Cc3ccccc3)CC2)cc1,Flunarizine,GST-Inducer,negative
196,COC(=O)c1c(C)nc(C)c(C(=O)O[C@H]2CCN(Cc3ccccc3)C2)c1-c1cccc([N+](=O)[O-])c1,barnidipine_M8,3A4-Substrate,negative
197,COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@H]2CCN(Cc3ccccc3)C2)[C@H]1c1cccc([N+](=O)[O-])c1,barnidipine,2D6-Substrate,negative
198,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CC,Etoperidone,2D6-Substrate,negative
199,CC(C)(C(=O)c1cccnc1)c1cccnc1,Metyrapone,2E1-Inhibitor,negative
200,CC[C@]1(C)CC(=O)NC1=O,Ethosuximide,2E1-Substrate,negative
201,CCCC(=O)Nc1ccc(OC[C@@H](O)CNC(C)C)c(C(C)=O)c1,Acebutolol,2D6-Inhibitor,negative
202,COc1ccc([C@H](CN(C)C)C2(O)CCCCC2)cc1,venlafaxine_R,2D6-Substrate,negative
203,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1,13_cis_retinoic_acid,2E1-Substrate,negative
204,COc1ccc2c(CN)cc(=O)oc2c1,MAMC,2D6-Substrate,negative
205,CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12,Chloroquine,Multidrug_and_toxin_extrusion_protein_1-Inhibitor,negative
206,O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1,Ziprasidone,P450_HFLA-Substrate,negative
207,CC(=O)Nc1nnc(S(N)(=O)=O)s1,Acetazolamide,-,negative
208,O[C@@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1,Nebivolol,2D6-Substrate,negative
209,O=C(O)c1ccc(OCCn2ccnc2)cc1,Dazoxiben,-,negative
210,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1C=CC(=O)OC(C)(C)C,Lacidipine,-,negative
211,COc1ccc2cc(CCC(C)=O)ccc2c1,nabumetone,2E1-Substrate,negative
212,Cc1cc2ccccc2c2ccc3ccccc3c12,5_methylchrysene,2E1-Substrate,negative
213,NNCCc1ccccc1,Phenelzine,2C19-Inhibitor,positive
214,Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1,Sulfapyridine,-,negative
215,CN1C(=O)[C@](C)(C2=CCCCC2)C(=O)N=C1O,Hexobarbital,-,negative
216,CN1CCN(C2=Nc3ccccc3Sc3ccc(Cl)cc32)CC1,Clotiapine,P450_HFLA-Substrate,negative
217,C[C@@]12CC[C@H]3c4ccc(OC(=O)N(CCCl)CCCl)cc4CC[C@@H]3[C@@H]1CC[C@@H]2O,Estramustine,3A4-Substrate,negative
218,CCCCN1CCCC[C@@H]1C(=O)Nc1c(C)cccc1C,bupivacaine_R,2D6-Substrate,negative
219,C[C@@H]1Cc2c(Cl)cc(C(=O)N[C@@H](Cc3ccccc3)C(=O)O)c(O)c2C(=O)O1,ochratoxin_A,2C9-Substrate,negative
220,CCOP(=O)(Cc1ccc(C(=O)Nc2ccc(Br)cc2C#N)cc1)OCC,NO_1886,2C8-Substrate,negative
221,O=C(OC[C@H](O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12,Glafenine,ATP_binding_cassette_sub_family_G_member_2-Inhibitor,negative
222,Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,Desloratadine,2C19-Inhibitor,positive
223,Nc1ccc(Cc2ccc(N)c(Cl)c2)cc1Cl,MOCA,3A4-Substrate,negative
224,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,Amiodarone,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
225,CO[C@@]1(NC(=O)CSCC#N)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@@H]21,Cefmetazole,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
226,O=C1C(=C2Nc3ccc(S(=O)(=O)[O-])cc3C2=O)Nc2ccc(S(=O)(=O)[O-])cc21,Indigo Carmine,Coumarin_7_hydroxylase-Inhibitor,negative
227,CCN(CC)N=O,NN_diethyl_nitrosoamine,2E1-Substrate,negative
228,CC(C)NC[C@@H](O)COc1cccc2ccccc12,Propranolol,P450_HFLA-Substrate,negative
229,O=C(CCCN1CCC(O)(c2cccc(C(F)(F)F)c2)CC1)c1ccc(F)cc1,Trifluperidol,2D6-Substrate,negative
230,CC(=O)C[C@H](c1ccc([N+](=O)[O-])cc1)c1c(O)c2ccccc2oc1=O,Acenocoumarol,-,negative
231,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,Pravastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
232,C#CCN(C)Cc1ccccc1,Pargyline,2E1-Inhibitor,negative
233,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc2c1OCO2,Oxodipine,-,negative
234,COc1ccc2c(C(F)(F)F)cc(=O)oc2c1,7_methoxy_4_trifluoro_methyl_coumarin,2E1-Substrate,negative
235,CCCCC/C=C/C/C=C/CCCCCCCC(=O)O,linoleic_acid,2E1-Substrate,negative
236,NC(=O)OCC(COC(N)=O)c1ccccc1,Felbamate,2C19-Inhibitor,positive
237,CCOP(=S)(OCC)SCSCC,phorate,2C19-Substrate,negative
238,C[C@H](c1cc2ccccc2s1)N(O)C(N)=O,zileuton_R,2E1-Substrate,negative
239,CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C,Tenofovir Disoproxil,2E1-Inhibitor,negative
240,Cc1ccccc1[C@H](OCCN(C)C)c1ccccc1,Orphenadrine (citrate),2C19-Inhibitor,positive
241,C[C@H]1O[C@@H]1P(=O)(O)O,Fosfomycin,GST-Substrate,negative
242,CN1CCCC[C@H]1CCN1c2ccccc2Sc2ccc(S(C)=O)cc21,Mesoridazine,2D6-Substrate,negative
243,CC(=O)Oc1ccccc1C(=O)O,Acetylsalicylic Acid,GST-Inducer,negative
244,CCC[C@@H]1C(=O)N2C(N(C)C)=Nc3ccc(C)cc3N2C1=O,Azapropazone,-,negative
245,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,progesterone,2D6-Substrate,negative
246,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,Amprenavir,2C19-Inhibitor,positive
247,Cc1ccccc1,toluene,2E1-Substrate,negative
248,O=C(O)c1ccccc1Nc1cccc(C(F)(F)F)c1,Flufenamic Acid,2E1-Inducer,negative
249,CCCN1CCCC2Cc3nc(N)ncc3CC21,Quinelorane,-,negative
250,C[C@H](CN(C)C)CN1c2ccccc2Sc2ccc(C#N)cc21,Cyamemazine,2C9-Substrate,negative
251,CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,Methylergometrine,-,negative
252,CC(C)Cn1cnc2c(N)nc3ccccc3c21,Imiquimod,-,negative
253,COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)C=Cc2cc(OC)c(OC)c(OC)c2)[C@@H]1OC,Rescinnamine,Multidrug_resistance_protein_1-Inducer,negative
254,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@@H]1c1cccc([N+](=O)[O-])c1,Nimodipine,-,negative
255,CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,Escitalopram,2D6-Substrate,negative
256,Cn1c(N)nc2c3cccnc3ccc21,2_amino_3_methylimidazo_4_5_f_quinoline,1A2-Substrate,negative
257,CN1C(=O)NC(=O)[C@@](C)(C2=CCCCC2)C1=O,hexobarbital_R,2C19-Substrate,negative
258,CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21,Flurazepam,2E1-Inhibitor,negative
259,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSc4nnnn4C)CS[C@H]23)c2ccc(O)cc2)C(=O)C1=O,Cefoperazone,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
260,CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O,Idarubicin,2D6-Inhibitor,negative
261,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1,Alfentanil,P450_HFLA-Substrate,negative
262,COc1c(C)c2c(c(O)c1CC=C(C)CCC(=O)O)C(=O)OC2,Mycophenolic Acid,Solute_carrier_family_22_member_6-Substrate,negative
263,CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl,Etizolam,2C19-Substrate,negative
264,N[C@@H]1[C@@H](O)O[C@@H](CO)[C@H](O)[C@H]1O,Glucosamine,2E1-Substrate,negative
265,CCN(CC)C(=S)SC,DDTC_Me,2E1-Substrate,negative
266,Clc1ccc2nsnc2c1NC1=NCCN1,Tizanidine,1A2-Substrate,negative
267,Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,Folic Acid,2E1-Substrate,negative
268,O=C1C=C2CN(Cc3ccccc3Cl)CCC2S1,2_oxo_ticlopidine,2D6-Substrate,negative
269,O=C([O-])O,Sodium Bicarbonate,Electroneutral_sodium_bicarbonate_exchanger_1-Substrate,negative
270,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1,Vanoxerine,-,negative
271,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C,Dextropropoxyphene,P450_HFLA-Inducer,negative
272,COCc1c(C(C)C)nc(C(C)C)c(C=C[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1,Cerivastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
273,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,Fluphenazine,2E1-Inhibitor,negative
274,CCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1,Reboxetine,2D6-Inducer,negative
275,CCCC(C)Cn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_8,3A4-Substrate,negative
276,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1,Sufentanil,-,negative
277,O=C(O)CCCCC=C(c1ccccc1)c1cccnc1,Isbogrel,-,negative
278,CC(C)C(=O)Oc1ccc(CO)cc1[C@H](CCN(C(C)C)C(C)C)c1ccccc1,Fesoterodine,2D6-Substrate,negative
279,CCn1ncnc1COc1nn2c(-c3ccccc3F)nnc2cc1C(C)(C)C,TPA_023,3A4-Substrate,negative
280,Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,FLU,2C9-Substrate,negative
281,CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C,Pilocarpine,2E1-Substrate,negative
282,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1,Nefazodone,P450_HFLA-Inhibitor,negative
283,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,Sulfaphenazole,2D6-Inhibitor,negative
284,CCCCCC,hexane,2E1-Substrate,negative
285,Oc1ccc(C(c2ccc(O)cc2)C(Cl)(Cl)Cl)cc1,bis_OH_methoxychlor,3A4-Substrate,negative
286,CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21,Diazepam,2C19-Inhibitor,positive
287,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,Vinorelbine,2D6-Substrate,negative
288,CCN(CC)c1cc(C)nc2ncnn12,Trapidil,-,negative
289,CCN(CC)CCOCCOC(=O)C1(c2ccccc2)CCCC1,Pentoxyverine,2D6-Substrate,negative
290,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,Naproxen,SUL-Inhibitor,negative
291,Nc1nc([O-])c2c(n1)NCC(CNc1ccc(C(=O)NC(CCC(=O)[O-])C(=O)O)cc1)N2C=O.[Ca+2],Calcium folinate,-,negative
292,C[C@H](NCCc1ccc(O)cc1)[C@H](O)c1ccc(O)cc1,Ritodrine,SUL-Substrate,negative
293,Fc1cccc2c1OC1CNCC1O2,Fluparoxan,-,negative
294,CC(C)C[C@@H](N(C)C)C1(c2ccc(Cl)cc2)CCC1,Sibutramine,-,negative
295,CCC1(c2ccncc2)CCC(=O)NC1=O,Rogletimide,-,negative
296,[Cl-].[Na+],Sodium Chloride,2E1-Inducer,negative
297,CCN(CC)CC(=O)Nc1c(C)cccc1C,Lidocain,CP2CI-Substrate,negative
298,Clc1ccc2c(c1)C(c1ccccc1)=NCc1nncn1-2,Estazolam,3A4-Substrate,negative
299,O=[N+]([O-])c1ccc(O)cc1,4_nitrophenol,2E1-Substrate,negative
300,Cn1c(N)nc2ncc(-c3ccccc3)cc21,2_amino_1_methyl_6_phenylimidazo_4_5_b_pyridine,1A2-Substrate,negative
301,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,Decitabine,Methyltransferase-Inhibitor,negative
302,O=[As]1=[As](=O)O1,Arsenic Trioxide,1B1-Inhibitor,negative
303,O=c1ccc2nc3ccc(OCc4ccccc4)cc3oc-2c1,benzyl_oxy_resorufin,2D6-Substrate,negative
304,CCC(c1ccc(O)c(F)c1)C(C)c1ccc(O)c(F)c1,Bifluranol,-,negative
305,C[C@H](C#Cc1ccc(Cc2ccc(F)cc2)s1)N(O)C(N)=O,ABT_761,2E1-Substrate,negative
306,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Gemcitabine,Multidrug_resistance_associated_protein_5-Inducer,negative
307,CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3c(c2)OCO3)C1=O,Tadalafil,GST-Inducer,negative
308,C1CCN2C[C@H]3C[C@H](CN4CCCC[C@H]34)[C@@H]2C1,Sparteine,2D6-Inhibitor,negative
309,COCCc1ccc(OC[C@H](O)CNC(C)C)cc1,Metoprolol,2D6-Substrate,negative
310,O=NN(CCCl)C(=O)NC1CCCCC1,Lomustine,2D6-Substrate,negative
311,COC1=C[C@@H](C)[C@@H]2C[C@@H]3OC(=O)C[C@H]4C(C)=C(OC)C(=O)[C@H]([C@@]2(C)C1=O)[C@]34C,Quassia,1A1-Inhibitor,negative
312,OO,Hydrogen Peroxide,GST-Inhibitor,negative
313,CC[C@@H]1C(C)=NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc21,Tofisopam,3A4-Inhibitor,negative
314,CO[C@@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@@]3(CO3)C[C@H](C)[C@H](O[C@H]3O[C@@H](C)C[C@@H](N(C)C)[C@H]3O)[C@H]2C)O[C@@H](C)[C@H]1O,Oleandomycin,UGT-Substrate,negative
315,CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@@H](NC(=N)N)[C@H](O)[C@@H](NC(=N)N)[C@H](O)[C@H]3O)O[C@@H](C)[C@]2(O)CO)O[C@@H](CO)[C@H](O)[C@H]1O,Dihydrostreptomycin,3A4-Substrate,negative
316,CC(C)(C)C1CCC(C2=C(O)c3ccccc3C(=O)C2=O)CC1,58C80_tautomer_1,2C9-Substrate,negative
317,CSCC[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)O,Corticotropin,SUL-Inducer,negative
318,COc1c2occc2cc2ccc(=O)oc12,Methoxsalen,-,negative
319,CCNc1ncn(Cc2ccc(OC)c(OC3CCCC3)c2)c2nc(C(C)C)nc1-2,V_11294,2D6-Substrate,negative
320,Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1,Torasemide,2C19-Inhibitor,positive
321,O=C(O)CC[C@H]1[C@@H](NS(=O)(=O)c2ccccc2)C2CC[C@@H]1C2,tetranor,2C9-Substrate,negative
322,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,Tretinoin,Solute_carrier_family_28_member_3-Inducer,negative
323,COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,Zafirlukast,2C19-Inhibitor,positive
324,O=c1oc2ccccc2c(O)c1Cc1c(O)c2ccccc2oc1=O,Dicoumarol,GST-Inhibitor,negative
325,C/C=C/c1ccccc1,trans_phenylpropene,2E1-Substrate,negative
326,Cc1c(F)c(N2CCN[C@@H](C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1,Grepafloxacin,-,negative
327,CC[S@@](=O)c1c(C#N)nn(-c2c(Cl)cc(C(F)(F)F)cc2Cl)c1N,ethiprole,3A4-Substrate,negative
328,CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2,Molindone,2D6-Substrate,negative
329,Cc1ccccc1C,xylene_ortho,2E1-Substrate,negative
330,Cn1c(=O)c2[nH]cnc2n(C)c1=O,Aminophylline,2E1-Substrate,negative
331,CC[C@]12CCCN3CCc4c(n(c5ccccc45)[C@@](O)(C(=O)OC)C1)[C@@H]32,Vincamine,2E1-Substrate,negative
332,CNCC[C@@H](Oc1ccc(C(F)(F)F)cc1)c1ccccc1,Fluoxetine,2C19-Inhibitor,positive
333,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1,Mepyramine,2D6-Inhibitor,negative
334,CC(C)NC[C@H](O)c1ccc(O)c(O)c1,Isoprenaline,19A-Inducer,negative
335,C[C@@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1,flurbiprofen_R,2C9-Substrate,negative
336,Clc1cccc(N2CCNCC2)c1,m-Chlorophenylpiperazine,2D6-Substrate,negative
337,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,Topotecan,ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
338,CN1CCN(CCC=C2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1,Tiotixene,2D6-Inhibitor,negative
339,NC(=O)C1(N2CCCCC2)CCN(CCCC(=O)c2ccc(F)cc2)CC1,Pipamperone,GST-Inducer,negative
340,O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12,Trazodone,P450_HFLA-Substrate,negative
341,COc1ccccc1OC[C@H]1CNC(=O)O1,Mephenoxalone,Multidrug_and_toxin_extrusion_protein_1-Substrate,negative
342,CC[C@H](OC(C)=O)C(C[C@H](C)NC)(c1ccccc1)c1ccccc1,norLAAM,2D6-Substrate,negative
343,CCOc1ccc2ccccc2c1C(=O)NC1C(=O)N2C1SC(C)(C)C2C(=O)O,Nafcillin,-,negative
344,NS(=O)(=O)Cc1noc2ccccc12,Zonisamide,2C19-Inhibitor,positive
345,CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@H](c2ccccc2)NC(=O)[C@H]2CC(=O)[C@H](CS[C@@H]3CN4CCC3CC4)CN2C(=O)[C@H](Cc2ccc(N(C)C)cc2)N(C)C(=O)[C@@H]2CCCN2C1=O,Quinupristin/dalfopristin,3A4-Inhibitor,negative
346,C[C@@H](CCc1ccccc1)NC[C@H](O)c1ccc(O)c(C(N)=O)c1,Labetalol,2D6-Inhibitor,negative
347,COc1ccc2c(c1)N(C[C@H](C)CN(C)C)c1ccccc1S2,Levomepromazine,2E1-Inhibitor,negative
348,COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O,Ubidecarenone,Methyltransferase-Substrate,negative
349,CC(=O)[C@H]1CC[C@H]2[C@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@@H]3[C@H](O)C[C@]12C,Medrysone,2C19-Inhibitor,positive
350,C[C@@H]1CCc2cc(F)cc3c(=O)c(C(=O)O)cn1c23,Flumequine,2E1-Inhibitor,negative
351,C=CCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_12,3A4-Substrate,negative
352,CCN(CC)CC#CCOC(=O)[C@@](O)(c1ccccc1)C1CCCCC1,Oxybutynin,2D6-Inhibitor,negative
353,CCOCC,Diethyl Ether,2E1-Inducer,negative
354,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,Cholic Acid,SUL-Substrate,negative
355,CCCCCN(CCCCC)N=O,NN_diamyl_nitrosoamine,2E1-Substrate,negative
356,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,Telmisartan,2C19-Inhibitor,positive
357,CCO[C@H]1O[C@@H]2OC3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,beta_arteether,3A4-Substrate,negative
358,O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21,Fluorescein,Solute_carrier_family_22_member_6-Substrate,negative
359,COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC,Pantoprazole,2C19-Inhibitor,positive
360,CC(C)[C@H]1CC[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)O)CC1,Nateglinide,P450_HFLA-Substrate,negative
361,CCN[C@@H](C)Cc1ccccc1,Etilamfetamine,2D6-Substrate,negative
362,Cc1ncc(CO)c(CO)c1O,Pyridoxine (vit B6),Methyltransferase-Inhibitor,negative
363,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,Telithromycin,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
364,CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1,Betaxolol,2D6-Substrate,negative
365,CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1,Clindamycin,-,negative
366,CC(C(=O)O)c1ccc2c(c1)CC(=O)c1ccccc1S2,Zaltoprofen,-,negative
367,O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O,Niclosamide,-,negative
368,N=C(N)NCCN1CCCCCCC1,Guanethidine,3A4-Inducer,negative
369,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314,Hydrocodone,2D6-Substrate,negative
370,Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1,Tolcapone,Methyltransferase-Inhibitor,negative
371,c1ccc2c(c1)Sc1ccccc1N2C[C@@H]1CN2CCC1CC2,mequitazine,2D6-Substrate,negative
372,CCN(CC)C(=S)SSC(=S)N(CC)CC,Disulfiram,2E1-Substrate,negative
373,Nc1ccc(S(N)(=O)=O)cc1,Sulfanilamide,2C19-Inhibitor,positive
374,Nc1nc(NC2CC2)c2ncn([C@@H]3C=C[C@H](CO)C3)c2n1,Abacavir,-,negative
375,C(=C/c1ccccc1)\c1ccccc1,trans_stilbene,2D6-Substrate,negative
376,CCCCCCCCCCCCCCCCCC(=O)O,stearic_acid,2E1-Substrate,negative
377,CN(C)N=O,NN_dimethyl_nitrosoamine,2E1-Substrate,negative
378,CCOc1ccc2c(Cl)cc(=O)oc2c1,4_chloro_7_ethoxycoumarin,2C19-Substrate,negative
379,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,Raloxifene,19A-Inhibitor,negative
380,Nc1ccn(C[C@@H](CO)OCP(=O)(O)O)c(=O)n1,Cidofovir,Solute_carrier_family_22_member_6-Substrate,negative
381,O=C1CN(N=Cc2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C(=O)N1,Dantrolene,-,negative
382,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,montelukast,2D6-Substrate,negative
383,CCC[C@H](N[C@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC,Perindopril,GST-Inhibitor,negative
384,CCCCCCCC(C)O,2_nonanol,2E1-Substrate,negative
385,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,Captopril,Methyltransferase-Substrate,negative
386,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,Naloxone,2C8-Substrate,negative
387,COc1ccc2[nH]cc(CCN(C(C)C)C(C)C)c2c1,foxy,2D6-Substrate,negative
388,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O,Lornoxicam,-,negative
389,Cl,Hydrochloric Acid,2D6-Inhibitor,negative
390,CC(N)Cc1ccc(O)cc1,Hydroxyamfetamine,2D6-Substrate,negative
391,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,Ranitidine,2D6-Substrate,negative
392,O=[N+]([O-])OC1COC2C(O[N+](=O)[O-])COC12,Isosorbide dinitrate,-,negative
393,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,Hydrocortisone,GST-Inducer,negative
394,C=CC1CC=CCC1,4_vinylcyclohexene,2E1-Substrate,negative
395,NCC(=O)O,Glycine,GST-Inducer,negative
396,COC(=O)Nc1nc2cc(Sc3ccccc3)ccc2[nH]1,Fenbendazole,1A2-Inducer,negative
397,CCOP(=S)(OCC)SCCSCC,disulfoton,2D6-Substrate,negative
398,C=CCc1ccccc1OC[C@@H](O)CNC(C)C,Alprenolol,2D6-Substrate,negative
399,CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)O,Dinoprostone,19A-Inducer,negative
400,CN(C)C(=O)Nc1ccc(Cl)c(Cl)c1,diuron,2E1-Substrate,negative
401,Nc1ccc(-c2ccccc2)cc1,4_aminobiphenyl,1A2-Substrate,negative
402,Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl,Triclosan,SUL-Inhibitor,negative
403,O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],Glyceryl Trinitrate,GST-Inducer,negative
404,CN1CCN2c3ncccc3Cc3ccccc3[C@@H]2C1,mirtazapine_R,2D6-Substrate,negative
405,CC(C)NNC(=O)c1ccncc1,Iproniazide,N_acetyltransferase-Inhibitor,negative
406,CC(C)N=c1cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1,Clofazimine,-,negative
407,CCCCCCCCC=CCCCCCCCC(=O)O,Monoethanolamine Oleate,2E1-Substrate,negative
408,CC(C)(C)c1cc(CC2SCNC2=O)cc(C(C)(C)C)c1O,Tazofelone,-,negative
409,[Hg],"Mercury, Metallic",4A11-Inhibitor,negative
410,c1ccc2c(c1)ccc1nc3ccc4ccccc4c3cc12,dibenzacridine,1A2-Substrate,negative
411,COc1ccc(CCN(C)CCC[C@](C#N)(c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1OC,Gallopamil,-,negative
412,CC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C,Acetylcarnitine,Solute_carrier_family_22_member_5-Substrate,negative
413,CC12CCC(=O)C=C1C1CC1C1C2CCC2(C)C1C1CC1C21CCC(=O)O1,Drospirenone,-,negative
414,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,Valsartan,-,negative
415,COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1,Sulfadimethoxine,-,negative
416,COc1ccc(NC(C)=O)cc1,O_methyl_acetaminophen,1A2-Substrate,negative
417,O=C(O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1,Mitiglinide,UGT-Substrate,negative
418,O=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1,Anagrelide,1A2-Substrate,negative
419,Oc1ccccc1-c1ccccc1,O_phenylphenol,2E1-Substrate,negative
420,Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O,Febuxostat,UGT-Substrate,negative
421,C[C@H](C#Cc1ccc(Cc2ccc(F)cc2)s1)NC(N)=O,ABT_438,2E1-Substrate,negative
422,CN1C(=O)C(O)N=C(c2ccccc2)c2cc(Cl)ccc21,temazepam,2C19-Substrate,negative
423,Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1,flunarizine,2D6-Substrate,negative
424,C[C@@H](Cc1cccc(C(F)(F)F)c1)NCCOC(=O)c1ccccc1,Benfluorex,UGT-Inducer,negative
425,Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C,Sulfafurazole,-,negative
426,OC(CNCC(F)(F)F)COc1cccc2ccccc12,N_trifluoro_ethyl_desisopropyl_propranolol,2D6-Substrate,negative
427,CCNC(C)Cc1ccccc1,N_ethyl_amphetamine,2D6-Substrate,negative
428,OCCN1CCN(CCC=C2c3ccccc3Sc3ccc(Cl)cc32)CC1,Zuclopenthixol,2D6-Substrate,negative
429,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,Etoposide,2E1-Substrate,negative
430,CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1,Dexfenfluramine,2C19-Inhibitor,positive
431,C[N+](C)(C)C[C@H](O)CC(=O)[O-],Levocarnitine,2E1-Substrate,negative
432,C=C1CC[C@H](O)CC1=CC=C1CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,Colecalciferol,2C19-Inhibitor,positive
433,NS(=O)(=O)c1ccc(N2CCCCS2(=O)=O)cc1,Sultiame,N_acetyltransferase-Inducer,negative
434,C[C@]12C[C@@H]3C[C@](C)(C1)C[C@@](N)(C3)C2,Memantine,2C19-Inhibitor,positive
435,CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1,Proadifen,-,negative
436,O=NN1CCC[C@H]1c1cccnc1,N_nitroso_nornicotine,3A4-Substrate,negative
437,CCC(=O)[C@@]1(C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3CC[C@@]21C,Promegestone,SUL-Inducer,negative
438,C=CC#N,acrylonitrile,2E1-Substrate,negative
439,CCCCC[C@H](O)C=C[C@@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,Alprostadil,Multidrug_resistance_associated_protein_4-Substrate,negative
440,CN1CCN(C2=Nc3cc(F)ccc3Cc3ccccc32)CC1,Fluperlapine,2D6-Substrate,negative
441,CC1(C)Cc2c(-c3ccccc3)c(-c3ccc(Cl)cc3)c(CC(=O)O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)n2C1,licofelone_M1,2C8-Substrate,negative
442,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1c1cccc(Cl)c1Cl,Felodipine,P450_HFLA-Substrate,negative
443,C#C[C@]1(O)CC[C@H]2[C@H]3CCC4=CC(=O)CC[C@H]4[C@H]3C(=C)C[C@]21CC,Etonogestrel,-,negative
444,NC(=O)NN=Cc1ccc([N+](=O)[O-])o1,Nitrofural,2D6-Substrate,negative
445,CO[C@H](C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1,Plicamycin,Methyltransferase-Inhibitor,negative
446,CCCC(=O)O[C@H]1[C@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@@H]3[C@@H](OC)[C@H](O)CC(=O)O[C@H](C)CC=CC=C[C@H](O)[C@H](C)C[C@@H]3CC=O)[C@H](O)[C@H]2N(C)C)C[C@@]1(C)OC(=O)CC,Rokitamycin,-,negative
447,COc1ccc(-c2cc(=O)c3c(O)c(OC)c(O)cc3o2)cc1OC,eupatilin,2E1-Substrate,negative
448,C[C@H](CN(C)C)CN1c2ccccc2CCc2ccccc21,Trimipramine,2D6-Substrate,negative
449,c1cnc(N2CCNCC2)nc1,1_PP,2D6-Substrate,negative
450,CC(CCC(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CCC12C,Chenodeoxycholic acid,-,negative
451,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,Acarbose,2E1-Inducer,negative
452,C[C@@H](CN1c2ccccc2Sc2ccccc21)N(C)C,Promethazine,2D6-Inhibitor,negative
453,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1,Lumiracoxib,Solute_carrier_family_22_member_6-Inhibitor,negative
454,CC1(C)Cc2c(-c3ccccc3)c(-c3ccc(Cl)cc3)c(CC(=O)O)n2C1,licofelone,2D6-Substrate,negative
455,Clc1ccc(CO[C@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,Miconazole,2C19-Inhibitor,positive
456,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,Timolol,2D6-Substrate,negative
457,CC(C)(Oc1ccc([C@H]2CC2(Cl)Cl)cc1)C(=O)O,Ciprofibrate,4A11-Inducer,negative
458,Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1,Lu_AA21004,2D6-Substrate,negative
459,CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccc(O)cc3)[C@H]2SC1,Cefadroxil,Solute_carrier_family_15_member_2-Substrate,negative
460,COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@@H]2CCCN(Cc3ccccc3)C2)[C@H]1c1cccc([N+](=O)[O-])c1,Benidipine,2C19-Inhibitor,positive
461,CN1[C@H]2CCC[C@@H]1C[C@@H](NC(=O)c1nn(C)c3ccccc13)C2,Granisetron,2D6-Substrate,negative
462,CN(C)Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,Adinazolam,-,negative
463,CN(CC(=O)O)C(=N)NP(=O)(O)O,Fosfocreatine,Methyltransferase-Inhibitor,negative
464,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@H]1c1cccc([N+](=O)[O-])c1,Nitrendipine,P450_HFLA-Substrate,negative
465,CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,Trifluoperazine,-,negative
466,CCC(C)CCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_7,3A4-Substrate,negative
467,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1,Tazarotene,2C8-Substrate,negative
468,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,Bromocriptine,-,negative
469,c1ccc2[nH]c(-c3cscn3)nc2c1,Tiabendazole,-,negative
470,Nc1nc(OCc2ccccc2)c2nc[nH]c2n1,O6_benzylguanine,1A2-Substrate,negative
471,NCCc1c[nH]c2ccc(O)cc12,5_hydroxy_tryptamine,2C19-Substrate,negative
472,O=C(O)c1cccnc1,Nicotinic Acid,2D6-Inhibitor,negative
473,CC(N)Cc1ccc2c(c1)OCO2,MDA_tenamfetamine,2D6-Substrate,negative
474,CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1,Ecabapide,-,negative
475,CC(C)NCCCOc1cccc2ccccc12,deshydroxy_propranolol,2D6-Substrate,negative
476,O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,Ciprofloxacin,2E1-Inducer,negative
477,CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1,Proguanil,2E1-Substrate,negative
478,O=S1OCC2C(CO1)C1(Cl)C(Cl)=C(Cl)C2(Cl)C1(Cl)Cl,endosulfan,2C19-Substrate,negative
479,OC(c1ccccc1)(c1ccccc1)C1CCNCC1,Azacyclonol,-,negative
480,O=C(O)Cc1cc(O)ccc1Nc1c(Cl)cccc1Cl,5_hydroxy_diclofenac,2C9-Substrate,negative
481,CC1O[C@@]2(CS1)CN1CCC2CC1,Cevimeline,2D6-Substrate,negative
482,CN(CCOc1ccc(C[C@@H]2SC(=O)NC2=O)cc1)c1ccccn1,Rosiglitazone,2C19-Inhibitor,positive
483,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,Nelfinavir,2C19-Inhibitor,positive
484,CCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,Methylprednisolone Aceponate,3A4-Inducer,negative
485,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C,Norethisterone,P450_HFLA-Substrate,negative
486,CN(C)c1ccc(C2CC3(C)C(CCC3(O)C=CCO)C3CCC4=CC(=O)CCC4=C23)cc1,Lilopristone,-,negative
487,CCCC(CCC)C(=O)O,Valproic Acid,2C19-Inhibitor,positive
488,CC(C)(C=O)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,w_aldehyde_finasteride,3A4-Substrate,negative
489,CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)[C@@H](CO)c1ccccc1)C2,Atropine,1A2-Inhibitor,negative
490,CCNCc1cc(=O)oc2cc(OC)ccc12,EMAMC,2D6-Substrate,negative
491,O=c1[nH]cc(F)c(=O)[nH]1,Fluorouracil,-,negative
492,C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@H]3CC[C@@H](C(=O)N(C)C)N3)[C@H](C)[C@H]12,Meropenem,Solute_carrier_family_22_member_6-Substrate,negative
493,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,Pazopanib,3A4-Inhibitor,negative
494,COC(=O)C1C(O)CCC2CN3CCc4c([nH]c5ccccc45)C3CC21,Yohimbine,2D6-Substrate,negative
495,Clc1ccc(CS[C@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,Sulconazole,2C19-Inhibitor,positive
496,CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc21)OCOC(=O)C(C)(C)C,Adefovir Dipivoxil,2C9-Inhibitor,negative
497,O=C1CN=C(c2ccccn2)c2cc(Br)ccc2N1,Bromazepam,2E1-Inhibitor,negative
498,CNCCC=C1c2ccccc2CCc2ccccc21,Nortriptyline,2E1-Inhibitor,negative
499,CCN(CC)CCOC(=O)c1ccc(N)cc1,Procaine,Methyltransferase-Inhibitor,negative
500,CC(O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,Lisofylline,-,negative
501,C[C@H]1[C@@H]2CC[C@H](C)[C@H]3CC[C@]4(C)OO[C@]23[C@@H](O[C@@H]1OC(=O)CCC(=O)O)O4,Artesunate,-,negative
502,O=c1[nH]c2cc(Cl)ccc2o1,chlorzoxazone,2E1-Substrate,negative
503,c1ccc([C@H]2CN3CCSC3=N2)cc1,Levamisole,GST-Inducer,negative
504,N=O,Nitric Oxide,GST-Inducer,negative
505,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,Ketoconazole,2C19-Inhibitor,positive
506,CN(C)CCOc1ccc(C(=C(CCCl)c2ccccc2)c2ccccc2)cc1,Toremifene,-,negative
507,CN(C)C(=O)Oc1ccc[n+](C)c1,Pyridostigmine,3A4-Inducer,negative
508,CNC[C@@H](O)c1ccc(O)cc1,Oxedrine,N_acetyltransferase-Inhibitor,negative
509,COC1=CC(=O)OC1C(O)c1ccccc1Cl,Losigamone,-,negative
510,O=C1CC(=O)N(c2ccccc2)c2cc(Cl)ccc2N1,N_desmethyl_clobazapam,2C19-Substrate,negative
511,C=CCN,Trastuzumab,19A-Inhibitor,negative
512,CNCCCN1c2ccccc2CCc2ccc(Cl)cc21,N_desmethyl_clomipramine,2D6-Substrate,negative
513,CN[C@H](C)Cc1ccc2c(c1)OCO2,MDMA_R,2D6-Substrate,negative
514,N=C(N)NC[C@H]1COc2ccccc2O1,Guanoxan,2D6-Substrate,negative
515,O=C(O)c1cccnc1Nc1cccc(C(F)(F)F)c1,Niflumic Acid,Monocarboxylate_transporter_1-Inhibitor,negative
516,CN[C@@H](C)Cc1ccccc1OC,Methoxyphenamine,2D6-Substrate,negative
517,CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](CC=C(C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)C=CC=C3CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2,Ivermectin,-,negative
518,CO[C@@]12CC[C@]3(C[C@H]1[C@](C)(O)C(C)(C)C)[C@@H]1Cc4ccc(O)c5c4[C@]3(CCN1CC1CC1)[C@@H]2O5,Buprenorphine,2C19-Inhibitor,positive
519,NC(=O)N1c2ccccc2C[C@H](O)c2ccccc21,Eslicarbazepine,UGT-Substrate,negative
520,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2,Palonosetron,2D6-Substrate,negative
521,Cc1cccc(CN2CCN([C@@H](c3ccccc3)c3ccc(Cl)cc3)CC2)c1,Meclozin,1A2-Inhibitor,negative
522,CCN(CC)C(=O)Nc1ccc(OC[C@@H](O)CNC(C)(C)C)c(C(C)=O)c1,Celiprolol,Solute_carrier_organic_anion_transporter_family_member_1A2-Substrate,negative
523,CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1,Nimesulide,2C9-Inhibitor,negative
524,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,Celecoxib,SUL-Inhibitor,negative
525,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,Gefitinib,2C19-Inhibitor,positive
526,O=C(OC1CC2CCC(C1)[N+]21CCCC1)C(O)(c1ccccc1)c1ccccc1.[Cl-],Trospium chloride,-,negative
527,COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1,Buflomedil,2D6-Substrate,negative
528,COc1ccc(C(c2ccc(O)cc2)C(Cl)(Cl)Cl)cc1,mono_OH_methoxychlor,2E1-Substrate,negative
529,C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,Fulvestrant,3A4-Substrate,negative
530,Cn1cnc2c1c(=O)n(CC1CCCO1)c(=O)n2C,theobromine_deriv_9,3A4-Substrate,negative
531,CN1CCC(=C2c3ccccc3CCc3cccnc32)CC1,Azatadine,-,negative
532,CC[C@H](C)C[C@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O,Caspofungin,3A4-Inhibitor,negative
533,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1,Dipyridamole,Multidrug_resistance_associated_protein_1-Inhibitor,negative
534,NC(Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)[O-].[Na+],Levothyroxine sodium,-,negative
535,c1ccc2c(c1)ccc1ccccc12,phenanthrene,1A2-Substrate,negative
536,CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(=O)O,Unoproston,Solute_carrier_organic_anion_transporter_family_member_1A2-Substrate,negative
537,Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1,Gemfibrozil,2C19-Inhibitor,positive
538,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21,Norfloxacin,P450_HFLA-Inhibitor,negative
539,CCC(C)C(=O)OC1CCC=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21,Mevastatin,-,negative
540,C[C@H](C(=O)O)c1ccc2oc(-c3ccc(Cl)cc3)nc2c1,Benoxaprofen,1A2-Inducer,negative
541,CNC(=NC#N)NCCSCc1nc[nH]c1C,Cimetidine,2C19-Inhibitor,positive
542,CN/C(=C\[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,ranitidine,2D6-Substrate,negative
543,CN(CCCC(=O)c1cccnc1)N=O,NNK,2E1-Substrate,negative
544,Cc1c(N(C)C)c(=O)n(-c2ccccc2)n1C,Aminophenazone,2C19-Inhibitor,positive
545,[Se],Selenium Compounds,Methyltransferase-Inhibitor,negative
546,COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC,Trimethoprim,Multidrug_and_toxin_extrusion_protein_1-Inhibitor,negative
547,O=C(O)CC(O)(CC(=O)O)C(=O)[O-],Sodium Citrate,SUL-Inhibitor,negative
548,C=CC(=C)C,isoprene,2E1-Substrate,negative
549,O=[P@@]1(N(CCCl)CCCl)NCCCO1,Cyclophosphamide,CP2CI-Substrate,negative
550,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,Clopidogrel,-,negative
551,CCN(CC)CCCN(c1ccccc1)C1Cc2ccccc2C1,Aprindine,2D6-Substrate,negative
552,Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1,Sulfamethizole,-,negative
553,CC(=O)Nc1ccc(OC(C)C)cc1,O_isopropyl_acetaminophen,1A2-Substrate,negative
554,O=C(NC1CCSC2CCCC(C(=O)O)N2C1=O)C(S)Cc1ccccc1,Omapatrilat,-,negative
555,CN1C(=O)OC(C)(C)C1=O,Trimethadione,2E1-Substrate,negative
556,Cc1cc(CCCOc2c(C)cc(-c3noc(C(F)(F)F)n3)cc2C)on1,Pleconaril,P450_HFLA-Inducer,negative
557,CNCc1cc(=O)oc2cc(OC)ccc12,MMAMC,2D6-Substrate,negative
558,COc1ccc(-c2cc(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]5O)[C@H](O)[C@H](O)[C@H]4O)cc3o2)cc1O,Diosmin,Methyltransferase-Inhibitor,negative
559,N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,Letrozole,19A-Inhibitor,negative
560,Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2,Pilsicainide,-,negative
561,COc1ccc(OC)c([C@@H](O)[C@@H](C)N)c1,Methoxamine,Solute_carrier_family_12_member_2-Inducer,negative
562,CN(C)CCO[C@@H](c1ccc(Cl)cc1)c1ccccn1,Carbinoxamine,2E1-Substrate,negative
563,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CCC2=O,androstenedione,3A4-Substrate,negative
564,CN1C(=O)C[C@H](c2ccccc2)C1=O,Phensuximide,2C19-Inhibitor,positive
565,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@@H]3C[C@@H]12,Tetracycline,GST-Inhibitor,negative
566,S=P(N1CC1)(N1CC1)N1CC1,Thiotepa,GST-Substrate,negative
567,O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,Efavirenz,2C19-Inhibitor,positive
568,CCC1CC2CC3c4[nH]c5ccc(OC)cc5c4CCN(C2)C13,12_methoxy_ibogamine,2D6-Substrate,negative
569,CCN(CC)C(=O)N1CCN(C)CC1,Diethylcarbamazine,GST-Inducer,negative
570,Cc1nc2c([nH]1)c(=O)n(C)c(=O)n2Cc1ccco1,Furafylline,-,negative
571,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O,1_alpha_hydroxy_vitamin_D3,3A4-Substrate,negative
572,CNC(=O)Oc1cccc2c1OC(C)(C)C2,carbofuran,2D6-Substrate,negative
573,CN(N=O)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O,Streptozocin,2E1-Inducer,negative
574,O=C1[C@@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,Ezetimibe,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
575,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,Pentoxifylline,GST-Inducer,negative
576,CCCCOC(=O)C(=O)Nc1cccc(-c2nn[nH]n2)c1,Tazanolast,-,negative
577,CC(=O)NCC1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,Linezolid,-,negative
578,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,Levofloxacin,-,negative
579,CCC(C(=O)c1ccc(C)cc1)N1CCCC1,MPBP,2D6-Substrate,negative
580,CCCCC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1,Propiverine,3A4-Inhibitor,negative
581,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@@H]2C[C@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,Clarithromycin,2C19-Inhibitor,positive
582,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,Vinblastine,2D6-Substrate,negative
583,CCOc1ccc2c(C(F)(F)F)cc(=O)oc2c1,7_ethoxy_4_trifluoro_methyl_coumarin,2E1-Substrate,negative
584,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CCC2=O,Prasterone,19A-Substrate,negative
585,C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4,Artemisinin,GST-Inhibitor,negative
586,CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,Ropivacaine,2D6-Substrate,negative
587,CN1CCN(CCCCN2C(=O)CN(N=Cc3ccc(-c4ccc(Cl)cc4)o3)C2=O)CC1,Azimilide,-,negative
588,COc1cc2c(cc1OC)[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2,Tetrabenazine,2D6-Inhibitor,negative
589,COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c[nH]c2c1,BPR_0L075,2E1-Substrate,negative
590,C[C@@H](NC(=Nc1ccncc1)NC#N)C(C)(C)C,Pinacidil,2D6-Substrate,negative
591,C=C(CC)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl,Etacrynic Acid,GST-Substrate,negative
592,N=C(N)NC(=O)c1nc(Cl)c(N)nc1N,Amiloride,Solute_carrier_family_22_member_1-Inhibitor,negative
593,FC(F)O[C@@H](Cl)C(F)(F)F,Isoflurane,2E1-Substrate,negative
594,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Imatinib,P450_HFLA-Substrate,negative
595,CN(C)CCC=C1c2ccccc2COc2ccccc21,Doxepin,GST-Inhibitor,negative
596,C=C1CC[C@@H](O)CC1=CC=C1CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O,Calcifediol,24A-Substrate,negative
597,COc1ccc(CCN(C)CCC[C@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,verapamil_R,2C8-Substrate,negative
598,CN(C)CCC[C@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,Citalopram,2C19-Inhibitor,positive
599,C=CCCCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_10,3A4-Substrate,negative
600,Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1,Bupranolol,2D6-Substrate,negative
601,CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1,Atenolol,3A4-Substrate,negative
602,C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@]21CCC(=O)O1,Canrenone,UGT-Inhibitor,negative
603,CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O,Benzylpenicillin,Canalicular_multispecific_organic_anion_transporter_1-Inducer,negative
604,CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,Budesonide,SUL-Substrate,negative
605,OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O,Galactose,SUL-Substrate,negative
606,CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1,Probenecid,2C19-Inhibitor,positive
607,CCCCNCc1cc(=O)oc2cc(OC)ccc12,BMAMC,2D6-Substrate,negative
608,CN(C)C=O,DMF,2E1-Substrate,negative
609,CC(C)N1CCN(c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,Terconazole,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor,negative
610,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC,Levonorgestrel,19A-Inhibitor,negative
611,CCCCOc1ccc2ccc(=O)oc2c1,7_butoxy_coumarin,3A4-Substrate,negative
612,CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,Pyrimethamine,GST-Inhibitor,negative
613,CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)C(=O)[C@]3(CO3)C[C@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@H]2C)O[C@@H](C)[C@@H]1OC(C)=O,Troleandomycin,2C19-Inhibitor,positive
614,N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O,Glutathione,19A-Inducer,negative
615,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](c6cccs6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,Teniposide,-,negative
616,CC(C)(Oc1ccc(Cl)cc1)C(=O)O,Clofibric acid,-,negative
617,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,Hydromorphone,2D6-Substrate,negative
618,COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)cc1,muraglitazar,2E1-Substrate,negative
619,CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1,Melperone,2D6-Inhibitor,negative
620,CCNc1nc(NC(C)C)nc(SC)n1,ametryne,2C19-Substrate,negative
621,FC(F)(F)[C@@H](Cl)Br,Halothane,2E1-Substrate,negative
622,Cc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1,Rupatadine,-,negative
623,COc1ccc(C(=O)[C@@H](C)N2CCCC2)cc1,MOPPP_R,2D6-Substrate,negative
624,CC(C)(C)C(O)C=Cc1ccc2c(c1)OCO2,Stiripentol,-,negative
625,COc1ccc2c3c([nH]c2c1)C(C)=NCC3,harmaline,2D6-Substrate,negative
626,CC(NCCCOc1cccc2ccccc12)C(F)(F)F,deshydroxy_trifluoro_propranolol,2D6-Substrate,negative
627,CC1(C)[C@@H](C=C(Cl)Cl)[C@H]1C(=O)OCc1cccc(Oc2ccccc2)c1,Permethrin,2B6-Inducer,negative
628,CCCCCCCCCCCCCCCC(=O)O,palmitic_acid,2E1-Substrate,negative
629,CN(C)CCn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3csc(N)n3)[C@H]2SC1,Cefotiam,Solute_carrier_family_22_member_8-Substrate,negative
630,CCC1(CC)C(=O)NC(=O)N(C)C1=O,Metharbital,1B1-Inducer,negative
631,CC12CCC(O)CC1=CCC1C2CCC2(C)C(c3cccnc3)=CCC12,Abiraterone,-,negative
632,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1,Oxaprozin,2C9-Substrate,negative
633,CCCCc1nc(Cl)c(C=O)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,losartan_carboxaldehyde_EXP_3179,2C9-Substrate,negative
634,O=S1(=O)OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2ccccc21,Phenolsulfonphthalein,Solute_carrier_family_22_member_8-Substrate,negative
635,OCCc1ccccc1Nc1c(Cl)cccc1Cl,diclofenac_deriv_2,2C19-Substrate,negative
636,OCCCOc1cccc(CN2CCCCC2)c1,roxatidine_m5,2D6-Substrate,negative
637,Cc1ncc(COP(=O)(O)O)c(C=O)c1O,Pyridoxal Phosphate,SUL-Inhibitor,negative
638,CN1C(=O)C[C@@](C)(c2ccccc2)C1=O,Mesuximide,2C19-Inhibitor,positive
639,CC1COC2(c3ccccc3Cl)c3cc(Cl)ccc3NC(=O)CN12,Mexazolam,-,negative
640,CCn1nnc(C2=CCCN(C)C2)n1,LU_2509,2D6-Substrate,negative
641,CNC(=O)ON=C(C)SC,Methomyl,-,negative
642,CCCCN(CCCC)CC[C@@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12,halofantrine_R,2C8-Substrate,negative
643,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(c2ccccc2)c2ccccc2)[C@H]1c1cccc([N+](=O)[O-])c1,Lercanidipine,P450_HFLA-Substrate,negative
644,Oc1ncnc2[nH]ncc12,Allopurinol,2E1-Inhibitor,negative
645,C[C@H](S)C(=O)NCC(=O)O,Tiopronin,2E1-Inhibitor,negative
646,COc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314,Dihydrocodeine,2D6-Substrate,negative
647,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@@]21C,lithocholic_acid,3A4-Substrate,negative
648,CC(=O)N(C)c1cccc(-c2ccnc3c(C(=O)c4cccs4)cnn23)c1,indiplon,1A2-Substrate,negative
649,CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O,Phenoxymethylpenicillin,3A4-Inducer,negative
650,C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1,perhexiline,2D6-Substrate,negative
651,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,Atorvastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
652,CC(C)=O,Acetone,-,negative
653,COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,Dextromethorphan,2E1-Substrate,negative
654,CCC(C)(C)OC,tert_amyl_methyl_ether,2E1-Substrate,negative
655,FC(F)(F)C(Cl)Br,halothane,2E1-Substrate,negative
656,Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,Zidovudine,-,negative
657,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@H]2CC[C@@H]1N2C,Cocaine,GST-Inducer,negative
658,CN(C)CCC=C1c2ccccc2C=Cc2ccccc21,Cyclobenzaprine,2D6-Substrate,negative
659,CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1,Cefalexin,Multidrug_and_toxin_extrusion_protein_1-Substrate,negative
660,Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1,tolterodine,2D6-Substrate,negative
661,COc1cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2cc1OC,Oxypertine,Canalicular_multispecific_organic_anion_transporter_2-Inducer,negative
662,CCCCCCCCCCCC(=O)O,lauric_acid,2E1-Substrate,negative
663,CCN(CC)C(=O)NC1CC2c3cccc4[nH]cc(c34)CC2N(C)C1,Terguride,2D6-Substrate,negative
664,NC(=O)c1ccccc1O,Salicylamide,1B1-Inhibitor,negative
665,Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,Midazolam,P450_HFLA-Inhibitor,negative
666,NNc1nnc(NN)c2ccccc12,Dihydralazine,-,negative
667,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,Pimozide,2C19-Inhibitor,positive
668,CCOC(=O)n1ccn(C)c1=S,Carbimazole,-,negative
669,CN(C)C(=S)SSC(=S)N(C)C,Thiram,2E1-Substrate,negative
670,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3OC5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,etoposide,2E1-Substrate,negative
671,C1CCC(C(C[C@H]2CCCCN2)C2CCCCC2)CC1,Perhexiline,2D6-Substrate,negative
672,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2C(=O)CO,Desoxycortone,Steroid_11_beta_hydroxylase-Substrate,negative
673,C[C@@H]1NC(=O)[C@H](NC(=O)c2ncccc2O)[C@H](C)OC(=O)[C@@H](c2ccccc2)NC(=O)[C@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccc(N(C)C)cc2)N(C)C(=O)[C@H]2CCCN2C1=O,Virginiamycin,Methyltransferase-Inhibitor,negative
674,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,Alprazolam,P450_HFLA-Substrate,negative
675,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,Astemizole,P450_HFLA-Substrate,negative
676,COc1ccc2[nH]c([S@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,omeprazole_R,2C19-Substrate,negative
677,C[C@@H](O)[C@@H]1NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,Octreotide,Canalicular_multispecific_organic_anion_transporter_1-Substrate,negative
678,CN(C)CCCN1c2ccccc2CCc2ccccc21,Imipramine,2C19-Inhibitor,positive
679,[Li],Lithium,Solute_carrier_family_12_member_2-Inducer,negative
680,NC(=O)c1cnccn1,Pyrazinamide,1A2-Substrate,negative
681,C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,Bexarotene,-,negative
682,O=C(Cn1c(=O)sc2ccc(Cl)cc21)N1CCN(CCO)CC1,Tiaramide,-,negative
683,CON=C(C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[N+]3(C)CCCC3)CS[C@H]12)c1csc(N)n1,Cefepime,Solute_carrier_family_22_member_5-Inhibitor,negative
684,Cc1c(C)c2c(c(C)c1O)CC[C@](C)(COc1ccc(C[C@@H]3SC(=O)NC3=O)cc1)O2,Troglitazone,2C19-Inhibitor,positive
685,O=S(=O)([O-])[O-],Sodium Sulfate,P450_HP-Inducer,negative
686,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC=Cc2ccccc2)[C@H]1c1cccc([N+](=O)[O-])c1,Cilnidipine,-,negative
687,CCC1(C2=CCCCC2)C(=O)NC(=O)NC1=O,Cyclobarbital,HLp2-Inducer,negative
688,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21,Clomipramine,GST-Inhibitor,negative
689,CCc1ccc(CCOc2ccc(C[C@@H]3SC(=O)NC3=O)cc2)nc1,Pioglitazone,2C19-Inhibitor,positive
690,CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl,Clevidipine,2C9-Inhibitor,negative
691,CCN[C@H](C)Cc1ccc2c(c1)OCO2,MDE_R,2E1-Substrate,negative
692,CN(C/C=C/C#CC(C)(C)C)Cc1cccc2ccccc12,terbinafine,2C19-Substrate,negative
693,C[C@@H](C(=O)O)c1ccc(C(=O)c2ccccc2)s1,Tiaprofenic Acid,GST-Inhibitor,negative
694,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1,Tamsulosin,2D6-Substrate,negative
695,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@@]21C,deoxycholic_acid,3A4-Substrate,negative
696,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21,Enoxacin,-,negative
697,Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,Lamivudine,Solute_carrier_family_22_member_1-Substrate,negative
698,NN=O,Nitrosamine,-,negative
699,CNC(=S)Oc1cc(C)c(SC)c(C)c1,methiocarb,2D6-Substrate,negative
700,CC(=O)[C@@]1(C)CC[C@H]2[C@H]3C=C(C)C4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]21C,Medrogestone,3A4-Substrate,negative
701,CC(C)=C[C@@H]1[C@@H](C(=O)OCN2C(=O)C3=C(CCCC3)C2=O)C1(C)C,Tetramethrin,3A4-Inducer,negative
702,Cc1ccsc1C(=CCCN1CCC[C@@H](C(=O)O)C1)c1sccc1C,Tiagabine,2D6-Substrate,negative
703,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,Losartan,2C19-Inhibitor,positive
704,CSc1nc(-c2ccnc(NC(C)c3ccccc3)c2)c(-c2ccc(F)cc2)[nH]1,ML_3403,2D6-Substrate,negative
705,C=C[C@@H](N)CCC(=O)O,Vigabatrin,Proton_coupled_amino_acid_transporter_1-Substrate,negative
706,COC(=O)Nc1nc2cc(C(=O)c3ccccc3)ccc2[nH]1,Mebendazole,-,negative
707,[Ag],Silver,Probable_low_affinity_copper_uptake_protein_2-Inhibitor,negative
708,Cc1ccc(O)cc1,p_cresol,2E1-Substrate,negative
709,CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12,Eletriptan,2D6-Substrate,negative
710,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=C[C@H](O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,Cortisone,SUL-Inhibitor,negative
711,CCC1C2CC3C4N(C)c5ccccc5C45CC(C2C5O)N3C1O,Ajmaline,2D6-Inhibitor,negative
712,CC(C)=CCN1CCC2(C)c3cc(O)ccc3CC1C2C,Pentazocine,2D6-Substrate,negative
713,Clc1ccccc1CN1CCc2sccc2C1,Ticlopidine,2C19-Inhibitor,positive
714,N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(=O)O,Oxitriptan,Proton_coupled_amino_acid_transporter_1-Inhibitor,negative
715,CCN(CC)C(=O)SC,DETC_Me,2E1-Substrate,negative
716,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,Fluconazole,2C19-Inhibitor,positive
717,Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)Cn4cnnn4)[C@H]3SC2)s1,Cefazolin,Solute_carrier_family_22_member_6-Substrate,negative
718,O=C1CN=C(c2ccccc2)c2cc([N+](=O)[O-])ccc2N1,Nitrazepam,1A2-Inducer,negative
719,COc1ccc2cc(C#N)c(=O)oc2c1,7_methoxy_3_cyano_coumarin,2E1-Substrate,negative
720,O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)(O)O,Fosphenytoin,2C19-Inhibitor,positive
721,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1,Mirtazapine,2D6-Inhibitor,negative
722,CC(=O)Nc1ccc(O)cc1,Paracetamol,2E1-Inducer,negative
723,CCS(=O)(=O)CCn1c([N+](=O)[O-])cnc1C,Tinidazole,19A-Inhibitor,negative
724,CCC[C@@](C)(COC(N)=O)COC(=O)NC(C)C,Carisoprodol,-,negative
725,O=C1OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2ccccc21,Phenolphthalein,Canalicular_multispecific_organic_anion_transporter_1-Substrate,negative
726,Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1,Sulfamethoxazole,-,negative
727,C[C@H](CCC(=O)O)[C@@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,ursodeoxycholic_acid,3A4-Substrate,negative
728,NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O,Chlorothiazide,Solute_carrier_family_22_member_8-Substrate,negative
729,CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1,Brompheniramine,2E1-Substrate,negative
730,Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1,Sertaconazole,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor,negative
731,O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1,Chlorambucil,GST-Inducer,negative
732,CC1=C(C(=O)OCCN(Cc2ccccc2)c2ccccc2)C(c2cccc([N+](=O)[O-])c2)C(P2(=O)OCC(C)(C)CO2)=C(C)N1,Efonidipine,-,negative
733,Cc1onc(NS(=O)(=O)c2ccc(N)cc2)c1C,Sulfatroxazole,-,negative
734,N[C@@H]1CONC1=O,Cycloserine,Proton_coupled_amino_acid_transporter_1-Substrate,negative
735,CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO,Cortisol,-,negative
736,C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@@H]4[C@H](CC[C@]3(O)C2)[C@@]2(O)CC[C@H](C3=CC(=O)OC3)[C@@]2(C)C[C@H]4O)[C@H](O)[C@H](O)[C@H]1O,G-strophanthin,Multidrug_resistance_associated_protein_1-Inducer,negative
737,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,Diltiazem,P450_HFLA-Substrate,negative
738,CCN(CC)C(=O)c1cccc(C)c1,Diethyltoluamide,2E1-Substrate,negative
739,CC=CCC(C)C(=O)C1C(=O)NC(C(C)C)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C,Valspodar,-,negative
740,CC(C)[C@H](N)C(=O)OC[C@H](CO)OCn1cnc2c(=O)nc(N)[nH]c21,Valganciclovir,Solute_carrier_family_15_member_2-Inhibitor,negative
741,CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3,Apomorphine,SUL-Substrate,negative
742,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1c1cccc2nonc12,Isradipine,-,negative
743,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,Duloxetine,2D6-Substrate,negative
744,CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,Fingolimod,4F2-Substrate,negative
745,Cc1cn[nH]c1,Fomepizole,2E1-Inhibitor,negative
746,Nc1nc(C(=CCC(=O)O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=CCS[C@@H]23)cs1,Ceftibuten,Solute_carrier_family_15_member_1-Substrate,negative
747,CCC[N@@+]12[C@H]3C[C@@]45c6ccccc6N(C)[C@H]4[C@@H]1C[C@H]([C@@H]3[C@H]5O)[C@H](CC)[C@H]2O,Prajmaline,2D6-Substrate,negative
748,COc1ccc(C(=O)N2CCN(c3ccc4c(c3)CCC(=O)N4)CC2)cc1OC,Vesnarinone,-,negative
749,COc1ccc2c3c1OC1C(O)C=CC4C(C2)NCCC341,Norcodeine,2D6-Substrate,negative
750,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,Beclometasone,-,negative
751,CC(C)(CO)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,w_OH_finasteride,3A4-Substrate,negative
752,CC(=O)C[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O,warfarin_S,2C19-Substrate,negative
753,COc1ccc(CCN(C)CCC[C@@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,Verapamil,GST-Inducer,negative
754,CCOC(=O)[C@@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O,Enalapril,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
755,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,Chlorpromazine,2E1-Inhibitor,negative
756,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O,Diflunisal,UGT-Substrate,negative
757,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C,Mibefradil,P450_HFLA-Inhibitor,negative
758,CC[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O,phenprocoumon_S,2C19-Substrate,negative
759,CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN,Deferoxamine,1A1-Inhibitor,negative
760,CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl,chlorpyrifos,2D6-Substrate,negative
761,CN1C(=O)CC(=O)N(c2ccc(O)cc2)c2cc(Cl)ccc21,4prime_hydroxy_clobazam,2C19-Substrate,negative
762,CCC1CN2CCC1CC2C(O)c1ccnc2ccc(OC)cc12,Hydroquinidine,-,negative
763,CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,Fosamprenavir,2C19-Inhibitor,positive
764,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O,Idebenone,1A2-Substrate,negative
765,Cc1cc(Cl)c(S(N)(=O)=O)cc1S(N)(=O)=O,Disulfamide,-,negative
766,CCOP(=S)(OCC)Oc1cc(C)nc(C(C)C)n1,diazinion,2E1-Substrate,negative
767,NCCc1ccc(O)c(O)c1,Dopamine,19A-Inhibitor,negative
768,COc1ccc(CCNCCC[C@@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,norverapamil_S,2C8-Substrate,negative
769,CO[C@H]1C=CO[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,Rifaximin,3A4-Inducer,negative
770,COc1ccc(C(C)C)cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1,ezlopitant,2D6-Substrate,negative
771,CCC(N)Cc1ccc2c(c1)OCO2,BDB,2D6-Substrate,negative
772,CN1C(=O)CN=C(c2ccccc2F)c2cc([N+](=O)[O-])ccc21,Flunitrazepam,-,negative
773,CC(C)(C)NC[C@H](O)c1cc(Cl)c(N)c(Cl)c1,Clenbuterol,1A2-Substrate,negative
774,CC(C)c1cccc(C(C)C)c1O,Propofol,CP2CI-Substrate,negative
775,CN1CCCC1c1cccnc1,nicotine,2D6-Substrate,negative
776,COc1ccc([C@@H]2CC(=O)c3c(O)cc(O)cc3O2)cc1O,hesperetin,1A2-Substrate,negative
777,O=C(O[C@@H]1C[C@@H]2C[C@@H]3C[C@H](C1)N2CC3=O)c1c[nH]c2ccccc12,Dolasetron,2D6-Substrate,negative
778,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/CO)C(C)(C)CCC1,retinol,2D6-Substrate,negative
779,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,Sildenafil,2C19-Inhibitor,positive
780,CCCNCc1cc(=O)oc2cc(OC)ccc12,PMAMC,2D6-Substrate,negative
781,Cc1nc[nH]c1CN1CCc2c(c3ccccc3n2C)C1=O,Alosetron,2E1-Inhibitor,negative
782,NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1,Famotidine,-,negative
783,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O,Estrone,4A11-Substrate,negative
784,O=[N+]([O-])c1cncn1CCN1CCOCC1,Nimorazole,-,negative
785,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12,Benzydamine,2E1-Substrate,negative
786,CSc1ccc2c(c1)N(CC[C@@H]1CCCCN1C)c1ccccc1S2,Thioridazine,2E1-Inhibitor,negative
787,CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN1CCOCC1)c1ccccc1S2,Moracizine,-,negative
788,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,Mometasone,2C8-Inhibitor,negative
789,CN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2)CC1,Difloxacin,-,negative
790,CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12,Mitomycin,1A2-Inducer,negative
791,COc1cc(-c2cc3c(c(=O)o2)C[C@]2(O)[C@](C)(CC[C@@]4(O)C(C)(C)C=CC(=O)[C@@]42C)O3)cc2c1OCO2,territrem_A,2D6-Substrate,negative
792,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,Dasatinib,UGT-Inhibitor,negative
793,CC(C)(C)N1CCC(c2ccccc2)(c2ccccc2)CC1,Budipine,2D6-Inhibitor,negative
794,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,Loratadine,2C19-Inhibitor,positive
795,C=CCC1(C(C)C)C(=O)NC(=O)NC1=O,Aprobarbital,2B6-Inducer,negative
796,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3C(=C)C[C@@]21CC,Desogestrel,-,negative
797,COc1ccc(CCNCCC[C@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,norverapamil_R,2C8-Substrate,negative
798,COc1ccc([N+](=O)[O-])cc1,4_nitroanisole,2E1-Substrate,negative
799,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@@H]21,Yohimbin,2D6-Inhibitor,negative
800,CCCCCCNC(=N)NC(=N)N.Cl,Polihexanide,GST-Inhibitor,negative
801,COc1ccc2[nH]c(S(=O)Cc3ncc(C)c(OC)c3C)nc2c1,Omeprazole,2C19-Inhibitor,positive
802,c1ccc(-c2ccc([C@H](c3ccccc3)n3ccnc3)cc2)cc1,Bifonazole,2C19-Inhibitor,positive
803,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@@](C)(C(=O)O)CC[C@]3(C)CC[C@]21C,Enoxolone,Canalicular_multispecific_organic_anion_transporter_1-Inhibitor,negative
804,CN(C)CCC=C1c2ccccc2COc2ccc(CC(=O)O)cc21,Olopatadine,-,negative
805,O=C(CCCCCCC(=O)Nc1ccccc1)NO,Vorinostat,Methyltransferase-Inhibitor,negative
806,Cc1ccc(C(=CCN2CCCC2)c2ccccn2)cc1,Triprolidine,2D6-Inhibitor,negative
807,CO[C@H]1C=CO[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(C=NN5CCN(C6CCCC6)CC5)c(O)c4c3C2=O)NC(=O)C(C)=CC=C[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H]1C,Rifapentine,P450_HFLA-Inducer,negative
808,CCOP(=S)(OCC)Oc1ccc([N+](=O)[O-])cc1,parathion,2E1-Substrate,negative
809,c1ccc2c(c1)Sc1ccccc1N2C[C@H]1CN2CCC1CC2,Mequitazine,2D6-Substrate,negative
810,COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,Tramadol,2D6-Inhibitor,negative
811,CN1CCN([C@@H](c2ccccc2)c2ccc(Cl)cc2)CC1,Chlorcyclizine,Multidrug_resistance_associated_protein_1-Substrate,negative
812,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,Oxycodone,19A-Inhibitor,negative
813,CC(c1cc2ccccc2s1)N(O)C(N)=O,Zileuton,-,negative
814,C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,Voriconazole,2C19-Inhibitor,positive
815,CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1,Propafenone,2D6-Inhibitor,negative
816,NC(N)=Nc1nc(CSCCN=CNS(=O)(=O)c2ccc(Br)cc2)cs1,Ebrotidine,-,negative
817,O=C1C(CCS(=O)c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1,Sulfinpyrazone,-,negative
818,CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,Eszopiclone,2E1-Substrate,negative
819,CC(Cc1ccccc1)(NC(=O)CN)c1ccccc1,Remacemide,-,negative
820,CCCCNC(C)Cc1ccccc1,N_butyl_amphetamine,2D6-Substrate,negative
821,CCN(CC)C(=O)C(C#N)=Cc1cc(O)c(O)c([N+](=O)[O-])c1,Entacapone,2C19-Inhibitor,positive
822,O=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl,Tienilic Acid,GST-Inhibitor,negative
823,N=C(N)N1CCc2ccccc2C1,Debrisoquine,2D6-Substrate,negative
824,CC[C@H](C)[C@H]1NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(N)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@@H](CCC(N)=O)NC1=O,Vasopressin,Solute_carrier_family_12_member_1-Inducer,negative
825,CC(C)c1nc(CN(C)C(=O)N[C@@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,Ritonavir,2C19-Inhibitor,positive
826,N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,Melphalan,GST-Substrate,negative
827,CC(C)(C)NCC(O)COc1ccccc1C#N,Bunitrolol,2D6-Substrate,negative
828,CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1,Levacetylmethadol,19A-Substrate,negative
829,CC[C@H](Cc1ccc2c(c1)OCO2)NC,MBDB,2D6-Substrate,negative
830,COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)[C@H]1c1cccc([N+](=O)[O-])c1,Nilvadipine,2C19-Inhibitor,positive
831,Cc1c(O)cc2c(c1C)O[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC2,Tocopherol (vit E),2E1-Inhibitor,negative
832,O=[N+]([O-])O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-],Isosorbide Dinitrate,2E1-Inhibitor,negative
833,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)[C@@H]1c1ccccc1[N+](=O)[O-],Nisoldipine,P450_HFLA-Substrate,negative
834,Clc1ccc(CO[C@@H](C[C@H]2C=NC=N2)c2ccc(Cl)cc2Cl)cc1,Econazole,19A-Inhibitor,negative
835,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@H]1c1ccccc1Cl,Amlodipine,P450_HFLA-Substrate,negative
836,CCCN1CCC[C@@H](c2cccc(S(C)(=O)=O)c2)C1,OSU_6162,2D6-Substrate,negative
837,CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1,Chlorpropamide,2C19-Substrate,negative
838,CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1,Parecoxib,2D6-Inhibitor,negative
839,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)C=C(C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)C=CC=CC=C1C,Everolimus,-,negative
840,C1CNCCN1,Piperazine,2D6-Substrate,negative
841,C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12,Chinin,2C19-Inhibitor,positive
842,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1,Desvenlafaxine,2D6-Substrate,negative
843,C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](C[C@H]2C=Nc3ccccc32)NC[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN3CCN(CC(=O)O)CC(=O)O[In](OC(=O)C3)OC(=O)C2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,Indium (111In) Pentetic Acid,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
844,CCC1(CC)C(=O)NC[C@@H](C)C1=O,Methyprylon,2D6-Substrate,negative
845,COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1,fluvoxamine,2D6-Substrate,negative
846,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1,Buspirone,P450_HFLA-Substrate,negative
847,Nc1nc2c(ncn2COCCO)c(=O)[nH]1,Aciclovir,Canalicular_multispecific_organic_anion_transporter_1-Substrate,negative
848,COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,Glibenclamide,-,negative
849,N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H]1CSSCCC(=O)N[C@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,Desmopressin,Solute_carrier_family_12_member_1-Inducer,negative
850,O=C1C2CCCCC2C(=O)N1CCCCN1CCN(c2nsc3ccccc23)CC1,Perospirone,2D6-Substrate,negative
851,O=S(=O)([O-])[S-],Thiosulfate,2E1-Inhibitor,negative
852,Nc1ccc(C(=O)O)c(O)c1,Aminosalicylic Acid,Sodium_coupled_neutral_amino_acid_transporter_3-Substrate,negative
853,O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,Sulfasalazine,-,negative
854,OCC(CO)N[C@H]1C[C@@](O)(CO)[C@H](O)[C@@H](O)[C@@H]1O,Voglibose,2E1-Inducer,negative
855,O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl,Chloramphenicol,2C19-Inhibitor,positive
856,CCOC(=O)c1cncn1[C@@H](C)c1ccccc1,Etomidate,19A-Inhibitor,negative
857,CC(C)C(C)NCC(O)COc1cccc2ccccc12,isopropyl_propranolol,2D6-Substrate,negative
858,CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21,Emetine,2D6-Substrate,negative
859,CCN1C(=O)N[C@@H](c2ccccc2)C1=O,Ethotoin,2C19-Inhibitor,positive
860,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,Vincristine,P450_HFLA-Substrate,negative
861,CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,Neostigmine,P450_HFLA-Inhibitor,negative
862,CCn1cc(C(=O)O)c(=O)c2ccc(C)nc21,Nalidixic acid,-,negative
863,C=CCc1ccc2c(c1)OCO2,safrole,2E1-Substrate,negative
864,CCCN[C@@H]1CCc2nc(N)sc2C1,Pramipexole,-,negative
865,C#C[C@]1(O)CC[C@H]2[C@H]3[C@H](CC[C@@]21C)C1=C(CC(=O)CC1)C[C@H]3C,Tibolone,19A-Inhibitor,negative
866,CCCCN(C)N=O,NN_methyl_butyl_nitrosoamine,2E1-Substrate,negative
867,ClC(Cl)Cl,Chloroform,2E1-Substrate,negative
868,CO[C@H]1C=CO[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(C=NN5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,Rifampicin,4A11-Inducer,negative
869,O=C(O)CCC(=O)c1ccc(-c2ccccc2)cc1,Fenbufen,Multidrug_resistance_protein_1-Inducer,negative
870,CC(=O)OCC(CCn1cnc2cnc(N)nc21)COC(C)=O,Famciclovir,3A4-Substrate,negative
871,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)C1=O,9_alpha_fluoro_androstadienedione,3A4-Substrate,negative
872,CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,Mosapride,-,negative
873,CO[C@H]1C=CO[C@@]2(C)Oc3c(C)c(O)c4c(c3C2=O)C2=NC3(CCN(CC(C)C)CC3)NC2=C(NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C4=O,Rifabutin,-,negative
874,CCc1ccccc1,Ethylbenzene,-,negative
875,CCC(C)(C)NCC(O)COc1ccccc1C(=O)CCc1ccccc1,Diprafenone,2D6-Substrate,negative
876,COc1ccc([C@@H](CN(C)C)C2(O)CCCCC2)cc1,Venlafaxine,2D6-Inhibitor,negative
877,C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21,Tiotropium Bromide,2D6-Substrate,negative
878,CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1,Roquinimex,-,negative
879,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,Spironolactone,-,negative
880,OC[C@H]1O[C@@H](n2cnc3c(O)ncnc32)[C@H](O)[C@@H]1O,Inosine,Solute_carrier_family_28_member_3-Inhibitor,negative
881,OCC(O)CO,Glycerol,2E1-Inducer,negative
882,CC(C)N(CC[C@](C(N)=O)(c1ccccc1)c1ccccn1)C(C)C,Disopyramide,-,negative
883,CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1,Zaleplon,P450_HFLA-Substrate,negative
884,Cc1cccc(C)c1OC[C@H](C)N,Mexiletine,2E1-Substrate,negative
885,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,Dihydroergotamine,-,negative
886,Cc1nnc2n1-c1sc(Br)cc1C(c1ccccc1Cl)=NC2,Brotizolam,-,negative
887,Cn1nnc2c(C(N)=O)ncn2c1=O,Temozolomide,Methyltransferase-Inhibitor,negative
888,O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC1CC1,Prazepam,3A4-Substrate,negative
889,C=CCSSCC=C,diallylsulfide,2E1-Substrate,negative
890,CN(C)CCC=C1c2ccccc2CCc2ccccc21,Amitriptyline,2C19-Inhibitor,positive
891,CCCN(CCC)CCc1cccc2c1CC(=O)N2,Ropinirole,2D6-Inhibitor,negative
892,N[Pt](N)(Cl)Cl,Cisplatin,Probable_low_affinity_copper_uptake_protein_2-Substrate,negative
893,COc1ccc(CN2CCNCC2)c(OC)c1OC,Trimetazidine,-,negative
894,Fc1ccccc1C1=NCC(=S)N(CC(F)(F)F)c2ccc(Cl)cc21,Quazepam,2C19-Substrate,negative
895,COc1cc2c(c3oc(=O)c4c(c13)CCC4=O)[C@@H]1C=CO[C@@H]1O2,aflatoxin_B1,1A2-Substrate,negative
896,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@@H]2C[C@](C)(OC)[C@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@H]2O[C@@H](C)C[C@H](N(C)C)[C@@H]2O)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,Roxithromycin,-,negative
897,Cc1ccccc1-n1c(C)nc2ccccc2c1=O,Methaqualone,-,negative
898,C[C@@](N)(Cc1ccc(O)c(O)c1)C(=O)O,Methyldopa (levorotatory),GST-Inhibitor,negative
899,FC(F)OC(F)(F)[C@H](F)Cl,Enflurane,2E1-Substrate,negative
900,O=c1c(O)c(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,kaempferol,1A2-Substrate,negative
901,O=C(c1cccs1)c1ccc(O)c(Cl)c1Cl,tienilic_acid_deriv_1,2C9-Substrate,negative
902,c1ccc2ncccc2c1,quinoline,2E1-Substrate,negative
903,c1ccc(COc2ccc3cccnc3c2)cc1,7_benzyloxy_quinoline,1A2-Substrate,negative
904,C[C@H](CN(C)C)CN1c2ccccc2S(=O)(=O)c2ccccc21,Oxomemazine,-,negative
905,CCCCCCCCCCCCCC(=O)O,myristic_acid,2E1-Substrate,negative
906,O=C(O)COc1ccc(C(=O)c2cccs2)cc1,suprofen_desmethyl,2C9-Substrate,negative
907,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,Lovastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
908,O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,Ascorbic Acid (vit C),GST-Inhibitor,negative
909,OCc1cccnc1,Nicotinyl Alcohol (pyridylcarbinol),Coumarin_7_hydroxylase-Substrate,negative
910,CO[C@@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,Artemether,2D6-Substrate,negative
911,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O,Dirithromycin,-,negative
912,C=C1C(=CC=C2CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@H](O)C[C@H]1O,Alfacalcidol,Sterol_26_hydroxylase_Sterol_27_hydroxylase_Vitamin_D3_25_hydroxylase_5_beta_cholestane_3_alpha_7_alpha12_alpha_triol_27_hydroxylase-Substrate,negative
913,Cc1c2ccncc2c(C)c2c1[nH]c1ccccc12,ellipticine,2D6-Substrate,negative
914,CC(C)Oc1ccc2c(=O)c(-c3ccccc3)coc2c1,Ipriflavone,2C19-Inhibitor,positive
915,Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,lansoprazole_R,2C19-Substrate,negative
916,CNNCc1ccc(C(=O)NC(C)C)cc1,Procarbazine,1B1-Substrate,negative
917,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(C=Cc2ccc3ccc(Cl)cc3n2)c1,Montelukast,-,negative
918,NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1,Diclofenamide,2C9-Inducer,negative
919,COc1ccc(C(=O)Nc2ccccc2[C@H](C)CN2CCCCC2)cc1,Encainide,2D6-Substrate,negative
920,O=NN1CCCC1,N_nitroso_pyrrolidine,2E1-Substrate,negative
921,COc1ccccc1OCCNC[C@H](O)COc1cccc2[nH]c3ccccc3c12,carvedilol_S,2D6-Substrate,negative
922,COc1ccc(OC)c([C@H](O)CNC(=O)CN)c1,Midodrine,2D6-Inhibitor,negative
923,CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@H](Cl)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,Pimecrolimus,3A4-Substrate,negative
924,Nc1ccc(C(=O)NCC(=O)O)cc1,Aminohippuric Acid,Solute_carrier_family_22_member_6-Substrate,negative
925,C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12,Quinidine,2E1-Substrate,negative
926,CC(C)(C(=O)O)c1ccc([C@@H](O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,Fexofenadine,2D6-Inhibitor,negative
927,FC(F)OC(F)(F)C(F)Cl,enflurane,2E1-Substrate,negative
928,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C,Danazol,19A-Inhibitor,negative
929,CCN(C)N=O,NN_methyl_ethyl_nitrosoamine,2E1-Substrate,negative
930,CCCCCNC(=N)NN=Cc1c[nH]c2ccc(CO)cc12,Tegaserod,2E1-Inhibitor,negative
931,CCCN(CCC)N=O,NN_dipropyl_nitrosoamine,2E1-Substrate,negative
932,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(C=NNO)cc1)C1CCCCC1,Ximelagatran,2C9-Substrate,negative
933,COc1ccc(-c2nc3ccc(C4=NNC(=O)CC4C)cc3[nH]2)cc1,Pimobendan,-,negative
934,O=C(c1cccs1)c1ccc(OCc2nnn[nH]2)c(Cl)c1Cl,tienilic_acid_newderiv_9,2C9-Substrate,negative
935,CCC1(CCC(C)C)C(=O)NC(=O)NC1=O,Amobarbital,Coumarin_7_hydroxylase-Inducer,negative
936,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1,Sertindole,2D6-Substrate,negative
937,CN[C@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1,Frovatriptan,-,negative
938,Cc1nccn1C[C@@H]1CCc2c(c3ccccc3n2C)C1=O,ondansetron,2D6-Substrate,negative
939,C=CC[C@]1(O)CC[C@H]2[C@H]3CCC4=CCCC[C@H]4[C@@H]3CC[C@]21C,Allylestrenol,3A4-Substrate,negative
940,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,Medroxyprogesterone,-,negative
941,CNCCCN1c2ccccc2CCc2ccccc21,Desipramine,2C19-Inhibitor,positive
942,COc1ccc2[nH]cc(CCNC(C)=O)c2c1,Melatonin,19A-Inhibitor,negative
943,CN1CCN2c3ccccc3Cc3ccccc3[C@@H]2C1,mianserin_R,2D6-Substrate,negative
944,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O,Quinapril,Solute_carrier_family_15_member_2-Inhibitor,negative
945,Clc1ccc(CON=C(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,Oxiconazole,-,negative
946,O=c1ccc2ccccc2o1,Coumarin,-,negative
947,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1,Ketoprofen,GST-Inhibitor,negative
948,C[C@@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,Clobetasol,1A2-Inhibitor,negative
949,CC[Hg]Sc1ccccc1C(=O)[O-],Thiomersal,GST-Inhibitor,negative
950,CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1,rosiglitazone_R,2C9-Substrate,negative
951,CNCCN1C(=O)[C@H](OC(C)=O)[C@H](c2ccc(OC)cc2)Sc2ccccc21,N_desmethyl_diltiazem,3A4-Substrate,negative
952,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,Daunorubicin,-,negative
953,NCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,Norfluoxetine,2D6-Substrate,negative
954,NC(=O)N1c2ccccc2CC(=O)c2ccccc21,Oxcarbazepine,2C19-Inhibitor,positive
955,CS(=O)(=O)OCCCCOS(C)(=O)=O,Busulfan,GST-Substrate,negative
956,CN1/C(=C(/O)Nc2ccccn2)C(=O)c2sccc2S1(=O)=O,tenoxicam,2C9-Substrate,negative
957,C[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@H]2O,Nandrolone,19A-Substrate,negative
958,CN[C@@H](C)[C@@H](O)c1ccccc1,Pseudoephedrine,SUL-Substrate,negative
959,CC(NCC(O)COc1cccc2ccccc12)C(F)(F)F,trifluoro_propranolol,2D6-Substrate,negative
960,COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C,Tubocurarine,Methyltransferase-Inhibitor,negative
961,O=C1CC[C@@H](N2C(=O)c3ccccc3C2=O)C(=O)N1,Thalidomide,CP2CI-Substrate,negative
962,CC(C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O,Angiotensinamide,Methyltransferase-Inducer,negative
963,O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1,Bromperidol,2D6-Substrate,negative
964,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,Simvastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
965,Cc1onc(-c2c(F)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12,Flucloxacillin,-,negative
966,Cn1c(=O)c2c(ncn2C)n(C)c1=O,Caffeine,2E1-Substrate,negative
967,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O,Resiquimod,-,negative
968,COc1ccc2c(c1)Oc1cc(O)ccc1C21OC(=O)c2ccccc21,3_O_methyl_fluorescein,2C19-Substrate,negative
969,Cc1cc(O)cc(C)c1Cl,Chloroxylenol,2E1-Substrate,negative
970,COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1,Methylphenidate,-,negative
971,NC(=O)N1c2ccccc2C=Cc2ccccc21,Carbamazepine,2C19-Inhibitor,positive
972,CC(NCC(O)COc1cccc2ccccc12)C(C)(C)C,tert_butyl_propranolol,2D6-Substrate,negative
973,COc1ccc2c(CN(C)C)cc(=O)oc2c1,DiMMAMC,2D6-Substrate,negative
974,C[n+]1c2cc(N)ccc2cc2ccc(N)cc21.Cl.Nc1ccc2cc3ccc(N)cc3nc2c1.[Cl-],Acriflavinium Chloride,1B1-Inducer,negative
975,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,Clotrimazole,2C19-Inhibitor,positive
976,CN(C)CCC=C1c2ccccc2Sc2ccc(Cl)cc21,Chlorprothixene,3A4-Substrate,negative
977,COc1ccc2[n-]c(S(=O)Cc3ncc(C)c(OC)c3C)nc2c1,Esomeprazole,2C19-Substrate,negative
978,Cc1nccn1C[C@H]1CCc2c(c3ccccc3n2C)C1=O,Ondansetron,2E1-Substrate,negative
979,COc1cc(Br)c2oc(C3CCNCC3)cc2c1,Brofaromine,2D6-Substrate,negative
980,CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C/C=C/C=C/[C@H](OC(C)=O)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@H]1OC,miocamycin_Mb2,3A4-Substrate,negative
981,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,Betamethason,19A-Inducer,negative
982,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,Risperidone,P450_HFLA-Substrate,negative
983,C1=CCCCC1,cyclohexene,2E1-Substrate,negative
984,CCOC(=O)C(CCc1ccccc1)NC(C)C(=O)N(CC(=O)O)C1Cc2ccccc2C1,Delapril,-,negative
985,CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,Posaconazole,UGT-Substrate,negative
986,CC(C)CCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_6,3A4-Substrate,negative
987,O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3[C@H]2C1,Praziquantel,P450_HFLA-Substrate,negative
988,Cc1ccnc(NC(=O)[C@H](C)c2cccc(C(=O)c3ccccc3)c2)c1,Oxatomide,2D6-Inhibitor,negative
989,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,Perphenazine,CP2CI-Substrate,negative
990,O=[N+]([O-])NC1=NCCN1Cc1ccc(Cl)nc1,imidacloprid,2E1-Substrate,negative
991,CCCc1nc(C)c2c(=O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)[nH]n12,Vardenafil,HLp2-Substrate,negative
992,C(=Cc1ccccc1)CN1CCN(C(c2ccccc2)c2ccccc2)CC1,Cinnarizine,2D6-Substrate,negative
993,CN[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H]([C@@H](C)NC)CC[C@@H]3N)[C@@H]2O)OC[C@]1(C)O,Gentamicin,Canalicular_multispecific_organic_anion_transporter_1-Inducer,negative
994,CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1,Ebastine,-,negative
995,CN1C2CCC1CC(OC(c1ccccc1)c1ccccc1)C2,Benzatropine,2D6-Substrate,negative
996,Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,Azathioprine,Methyltransferase-Substrate,negative
997,C[C@]12CC[C@H]3[C@@H](CCC4=C(O)C(=O)CC[C@@]43C)[C@@H]1CCC2=O,Formestane,19A-Inhibitor,negative
998,Nc1c2c(nc3ccccc13)CCCC2,Tacrine,GST-Substrate,negative
999,CC(=O)N=c1sc(S(N)(=O)=O)nn1C,Methazolamide,2C19-Inhibitor,positive
1000,C[C@@H]1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)CCN1,Temafloxacin,1A2-Substrate,negative
1001,CCCSP(=S)(OCC)Oc1ccc(SC)cc1,sulprofos,2D6-Substrate,negative
1002,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O,Indinavir,2C19-Inhibitor,positive
1003,CCOC(=O)C=C(C)C=CC=C(C)C=Cc1c(C)cc(OC)c(C)c1C,Etretinate,19A-Inhibitor,negative
1004,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@H]2O[C@@H](C)C[C@@H](N(C)C)[C@@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,Erythromycin,P450_HFLA-Substrate,negative
1005,CN1CCN2c3ccccc3Cc3ccccc3[C@H]2C1,Mianserin,2D6-Substrate,negative
1006,COc1ccc(O)cc1,Mequinol,GST-Inducer,negative
1007,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,simvastatin_hydroxy_acid,2C8-Substrate,negative
1008,CCC[C@@H](C)C1(CC)C(=O)NC(=O)NC1=O,Pentobarbital,-,negative
1009,CC(C)O,Isopropanol,2C19-Inhibitor,positive
1010,O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1,Clonazepam,-,negative
1011,Cc1c2ccccc2nc2c1ccc1ccccc12,7_methyl_benzacridine,1A2-Substrate,negative
1012,OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,Sorbitol,1A2-Inhibitor,negative
1013,COc1ccc(-c2oc3cc(O)cc(O)c3c(=O)c2O)cc1,kaempferide,2C9-Substrate,negative
1014,CC(C)Cc1ccc([C@@H](C)C(=O)O)cc1,ibuprofen_R,2C9-Substrate,negative
1015,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,Doxycycline,-,negative
1016,NCCc1c[nH]cn1,Histamine,2E1-Inducer,negative
1017,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,Ribavirin,Solute_carrier_family_28_member_3-Substrate,negative
1018,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O,Benazepril,Aldosterone_synthase_ALDOS_Aldosterone_synthesizing_enzyme_Steroid_18_hydroxylase-Inhibitor,negative
1019,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,Androstanolone,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Substrate,negative
1020,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1,MK_0457_tozasertib,2D6-Substrate,negative
1021,CCC(=O)C1(c2cccc(O)c2)CCN(C)CC1,Ketobemidone,2B6-Substrate,negative
1022,C=C(C)c1ccc(OC)c(CN[C@H]2C3CCN(CC3)[C@H]2C(c2ccccc2)c2ccccc2)c1,ezlopitant_alkene_CJ_12_458,2D6-Substrate,negative
1023,CC1=CC[C@H]2[C@@H](C1)C2(C)C,delta_3_carene,2D6-Substrate,negative
1024,CC(=O)C1CCC2C3CCC4CC(C)(O)CCC4(C)C3CCC12C,Ganaxolone,-,negative
1025,CCN(CC)C(=O)C1(c2ccccc2)CC1CN,Milnacipran,-,negative
1026,C#C[C@]1(O)C=C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3C(=C)C[C@@]21C,org_30659_tosagestin,2C19-Substrate,negative
1027,C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)C(=NOCC(=O)O)c3csc(N)n3)[C@H]2SC1,Cefixime,Solute_carrier_family_15_member_1-Substrate,negative
1028,C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,Exemestane,19A-Inhibitor,negative
1029,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,Vindesine,-,negative
1030,N#C[Fe](C#N)(C#N)(C#N)(C#N)N=O,Nitroprusside,Solute_carrier_family_12_member_2-Inhibitor,negative
1031,CN1C2CC[C@H]1CC(OC(=O)c1c[nH]c3ccccc13)C2,tropisetron,2D6-Substrate,negative
1032,Clc1cccc(C(c2ccc3nc[nH]c3c2)n2ccnc2)c1,Liarozole,-,negative
1033,FCOC(C(F)(F)F)C(F)(F)F,Sevoflurane,2E1-Substrate,negative
1034,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,17_beta_estradiol,2C9-Substrate,negative
1035,CC(N)Cc1ccccc1,amphetamine,2D6-Substrate,negative
1036,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,Clemastine,2D6-Inhibitor,negative
1037,C[C@@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@H]2O,Estradiol,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
1038,COc1ccc2[nH]c3c([N+](=O)[O-])ccc4c3c(nn4CCCN(C)C)c2c1,pyrazolo_acridine,1A2-Substrate,negative
1039,CCCCNC(C)Cc1ccc(OC)cc1,4_methoxy_N_butylamphetamine,2D6-Substrate,negative
1040,O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,Cilostazol,2D6-Substrate,negative
1041,CN1C(CC(=O)c2ccccc2)CCCC1CC(O)c1ccccc1,Lobeline,-,negative
1042,Cc1c(-c2cnccn2)ssc1=S,Oltipraz,-,negative
1043,CCCCOC(=O)c1ccccc1C(=O)OCCCC,Dibutylphthalate,19A-Inducer,negative
1044,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,Candesartan,-,negative
1045,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],Nifedipine,2E1-Inhibitor,negative
1046,CC(C)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1ncc[nH]1)[C@H](C)O)[C@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@H](CC(C)C)C(=O)N[C@H](C(=O)O)C(C)C,Secretin,Ileal_sodiumbile_acid_cotransporter-Inducer,negative
1047,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,Bosentan,Sodiumbile_acid_cotransporter-Inhibitor,negative
1048,CC(C)[C@]12CC(=O)[C@@H](C)[C@H]1C2,beta_thujone,3A4-Substrate,negative
1049,Fc1cccc(CCN2CCN(CCCc3c[nH]c4ccc(-n5cnnc5)cc34)CC2)c1,L_775_606,2C8-Substrate,negative
1050,CC1(C)[C@@H](O[C@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@@](C)(C(=O)O)CC[C@]3(C)CC[C@]21C,Glycyrrhizic Acid,P450_HFLA-Inducer,negative
1051,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,Dexamethasone,4A11-Inducer,negative
1052,CC(C(=O)c1ccc2c(c1)OCO2)N1CCCC1,MDPPP,2D6-Substrate,negative
1053,CNC(=O)Oc1cc(C)c(SC)c(C)c1,Methiocarb,2D6-Substrate,negative
1054,O=C1C=C2CN(C(C(=O)C3CC3)c3ccccc3F)CCC2S1,R_95913,2D6-Substrate,negative
1055,OCCSCCCCCCCCCCSCCO,Tiadenol,UGT-Inducer,negative
1056,CCCOCCOC(=O)C1=C(C)NC(C)=C(C(=O)OCCOCCC)C1c1cccc([N+](=O)[O-])c1,Niludipine,-,negative
1057,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,Nilotinib,UGT-Inhibitor,negative
1058,C#CCC12CCC(=O)C=C1CCC1C3CCC(=O)C3(C)CCC12,Plomestane,-,negative
1059,C=C(C)C1CO1,isoprene_epoxide_2,2E1-Substrate,negative
1060,CCc1cccc2c3c([nH]c12)[C@](CC)(CC(=O)O)OCC3,Etodolac,Canalicular_multispecific_organic_anion_transporter_1-Inhibitor,negative
1061,Nc1nc2cc(Cl)ccc2o1,Zoxazolamine,-,negative
1062,N.N.O=C1O[Pt]OC(=O)C12CCC2,Carboplatin,3A4-Inducer,negative
1063,CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1C2=Cc1ccc(Cl)cc1,Lumefantrine,-,negative
1064,O=C1c2ccccc2C(=O)c2ccccc21,Anthraquinone,-,negative
1065,CN1CCN(C(c2ccccc2)c2ccccc2)CC1,Cyclizine,2C9-Inhibitor,negative
1066,c1ccc2cc(COC3CCNCC3)ccc2c1,Litoxetine,-,negative
